deoxycytidine has been researched along with Neoplasm Metastasis in 1156 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.09) | 18.7374 |
| 1990's | 19 (1.64) | 18.2507 |
| 2000's | 487 (42.13) | 29.6817 |
| 2010's | 597 (51.64) | 24.3611 |
| 2020's | 52 (4.50) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, D; Fang, J; Feng, C; He, L; Liang, W; Qin, X; Wang, Q | 1 |
| Babu, S; Bajaj, V; Bhat, G; Biswas, G; Bondarde, SA; Boya, RR; Choudhury, K; Gupta, S; Joshi, N; Khan, MA; Lakshmaiah, KC; Maksud, TM; Mamillapalli, G; Neve, RS; Patel, AA; Patel, JG; Patel, P; Patil, P; Raja, G | 1 |
| Hwang, JH; Kim, J; Kim, JH; Lee, JC; Lee, YS | 1 |
| Akouz, FK; Barbier, E; Bourgeois, V; Coriat, R; Dahan, L; Desrame, J; Edeline, J; Ghiringhelli, F; Lecomte, T; Louafi, S; Ly, VL; Malka, D; Manfredi, S; Michel, P; Molin, Y; Neuzillet, C; Perrier, H; Phelip, JM; Soularue, E; Terrebonne, E | 1 |
| Chao, Y; Lee, CY; Li, CP; Lin, LG; Yu, HY | 1 |
| Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
| Cai, L; Guo, X; Hu, X; Jiang, Z; Luo, J; Pan, Y; Shao, Z; Sun, T; Teng, YE; Wang, B; Wang, S; Wang, X; Wang, Z; Wu, J; Yan, M; Zhang, J; Zhao, Y | 1 |
| Bracco, OL; Frenkl, T; Freshwater, T; Keefe, S; Li, H; Li, M; Perini, R; Valiathan, C | 1 |
| Iyikesici, MS | 1 |
| Chen, C; Chen, T; Fu, S; He, LN; Hong, S; Li, H; Lin, Z; Wang, Y; Zhang, L; Zhang, X; Zhou, Y | 1 |
| Bouvet, M; Chawla, SP; Higuchi, T; Hoffman, RM; Kawaguchi, K; Miyake, K; Oshiro, H; Park, JH; Singh, SR; Sugisawa, N; Unno, M; Zhang, Z | 1 |
| Banerjee, RK; Caulfield, TR; Dutta, SK; Huang, HS; Madamsetty, VS; Mody, K; Mukhopadhyay, D; Pal, K; Thompson, JR; Wang, E; Yen, Y | 1 |
| Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X | 1 |
| Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z | 1 |
| Chen, T; Choy, E; Cote, GM; Demetri, G; George, S; Marino-Enriquez, A; Merriam, P; Morgan, J; Nathenson, MJ; Thornton, K; Wagner, AJ | 1 |
| Aravantinos, G; Demiri, S; Fountzilas, G; Koliou, GA; Lampropoulou, DI; Pectasides, D; Pentheroudakis, G; Psyrri, A; Razis, E; Samantas, E; Sgouros, J; Zagouri, F | 1 |
| Beringer, A; Fuchs, M; Garlipp, B; Hahn, L; Heinemann, V; Kukiolka, T; Kütting, F; Malfertheiner, P; Reiser, M; Waldschmidt, DT; Westphalen, CB | 1 |
| Apte, MV; Goldstein, D; Liu, AC; Mekapogu, AR; Murakami, T; Pang, TCY; Perera, CJ; Pirola, RC; Pothula, SP; Wilson, JS; Xu, Z | 1 |
| Akbulut, H; Aykan, F; Coskun, HS; Dane, F; Demirag, GG; Evrensel, T; Hayran, M; Isikdogan, A; Karabulut, B; Kilickap, S; Oksuzoglu, B; Ozdemir, F; Ozdemir, NY; Ozkan, M; Sevinc, A; Turna, H; Ustaoglu, MA; Yalcin, S; Yavuzsen, T; Yuce, D | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| André, T; Bekaii-Saab, T; Bridgewater, J; Cunningham, D; Goldstein, D; Jensen, LH; Knox, JJ; Koeberle, D; Lopes, A; Malka, D; McNamara, MG; Moehler, M; Okusaka, T; Shannon, J; Valle, JW; Wagner, AD; Wasan, H | 1 |
| Kasi, A; Paluri, RK; Posey, JA; Young, C | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Li, H; Meng, R; Rui, M; Shang, Y; Shi, F | 1 |
| Andrikou, K; Bernardini, L; Casadei-Gardini, A; Catanese, S; Falcone, A; Formica, V; Fornaro, L; Lencioni, M; Massa, V; Pecora, I; Rapposelli, GI; Riggi, L; Rovesti, G; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Catalano, M; Conca, R; D'Angelo, A; Ianza, A; Mini, E; Nobili, S; Palmieri, VE; Panella, B; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Antico, G; Cole, A; Doleh, Y; Malangone-Monaco, E; Noxon, V; Pishvaian, MJ | 1 |
| Griffin, JI; Ho, RJ; McConnachie, LA; Mu, Q; Perazzolo, S; Shen, DD; Yu, J; Zhu, L | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Cheng, X; Li, Y; Tian, Y | 1 |
| Chugh, P; Furukawa, M; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Kanai, M; Kawabe, K; Komatsu, Y; Nakamori, S; Okusaka, T; Ozaka, M; Sato, A; Shimizu, S; Sugimori, K; Tang, R; Ueno, M | 1 |
| Batra, SK; C Caffrey, T; Chhonker, YS; Chirravuri, R; Chugh, S; Grandgenett, PM; Gupta, R; Hollingsworth, MA; L Grem, J; Lele, SM; Leon, F; Mallya, K; Marimuthu, S; Murry, DJ; Nallasamy, P; Nimmakayala, RK; Ponnusamy, MP; Prajapati, DR; Rachagani, S; Rauth, S; Shailendra, GK | 1 |
| Aieta, M; Catalano, M; Conca, R; D'Angelo, A; Dreoni, L; Gasperoni, S; Ianza, A; Mini, E; Nobili, S; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Ho, TTB; Honda, M; Inui, H; Kaneko, S; Kawaguchi, K; Kitamura, Y; Komura, T; Kozaka, T; Mizukoshi, E; Nasti, A; Sakai, Y; Seki, A; Shiba, K; Wada, T; Yamashita, T | 1 |
| Batra, SK; Chirravuri-Venkata, R; Foster, JM; Jain, M; Kaushik, G; Lele, SM; Ly, QP; Malafa, MP; Mallya, K; Nallasamy, P; Nimmakayala, RK; Ponnusamy, MP; Rachagani, S; Rauth, S; Seshacharyulu, P; Singh, AB; Smith, LM; Vengoji, R | 1 |
| Slater, H | 1 |
| Assenat, E; Boissière-Michot, F; de Forges, H; Dupuy, M; Ho-Pun-Cheung, A; Lombard-Bohas, C; Lopez-Crapez, E; Mazard, T; Mineur, L; Mollevi, C; Portales, F; Samalin, E; Walter, T; Ychou, M | 1 |
| Curiel, TJ; Deng, Y; Gupta, HB; Kancharla, A; Kari, S; Kornepati, AVR; Li, R; Osta, E; Padron, AS; Reyes, RM; Sun, X; Svatek, RS; Vadlamudi, R; Wu, B; Zhang, D | 1 |
| Choi, KY; Han, G; Lee, SH; Ryu, WJ | 1 |
| Adachi, S; Chishima, T; Doi, T; Endo, I; Hasegawa, S; Ichikawa, Y; Ishikawa, T; Kito, A; Morita, S; Morita, T; Narui, K; Oba, M; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A; Yamamoto, S | 1 |
| Beg, MS; Brekken, RA; Du, W; Huang, H; Lorens, JB; Phinney, NZ; Toombs, JE; Wang, Z; Westcott, J; Wilkie, TM; Zhang, Y | 1 |
| Astaras, C; Borner, M; De Dosso, S; Fritsch, R; Meisel, A; Siebenhüner, AR; Szturz, P; Winder, T | 1 |
| Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Berger, AK; Bougatf, N; Busch, E; Hackert, T; Jäger, D; Springfeld, C; Werft, W | 1 |
| Burdio-Pinilla, F; Casasola-Sánchez, LE; Pereira-Rodríguez, JA; Radosevic, A; Sánchez-Velázquez, P; Visa, L | 1 |
| Alva, A; Bandini, M; Curran, C; Diamantopoulos, LN; Gallina, A; Grivas, P; Grunewald, CM; Gupta, S; Jain, RK; Lee, JL; McGregor, BA; Mossanen, M; Necchi, A; Niegisch, G; Olson, KM; Pond, GR; Ravi, P; Singh, P; Skelton, WP; Sonpavde, GP; Su, C; Tward, JD | 1 |
| Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Cho, IR; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK | 1 |
| Archibald, CJ; Hunt, JT; Pattarawat, P; Poloway, J; Wang, HR | 1 |
| Bartolini, G; Bernardini, L; Casadei-Gardini, A; Cucchetti, A; Frassineti, GL; Massa, V; Passardi, A; Rapposelli, IG; Vivaldi, C | 1 |
| Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Iwai, T; Kamata, K; Katanuma, A; Kataoka, T; Kato, N; Kawamoto, Y; Kojima, Y; Miyakawa, H; Miyamoto, A; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nishina, T; Okano, N; Okusaka, T; Oono, T; Ozaka, M; Sano, K; Shimizu, K; Shimizu, S; Shioji, K; Shirakawa, H; Sudo, K; Sugimori, K; Takahashi, H; Tobimatsu, K; Todaka, A; Ueno, M; Yamaguchi, H; Yamamoto, T; Yamashita, T; Yasuda, I | 1 |
| Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ | 1 |
| Baron, MK; Garrido-Laguna, I; Haaland, B; Moser, JC; Nevala-Plagemann, C; Wang, X | 1 |
| Abuelafia, AM; Bigonnet, M; Chuluyan, E; Cros, J; Dusetti, N; Fraunhoffer, NA; Gayet, O; Iovanna, J; Nicolle, R; Palazzo, L; Teyssedou, C | 1 |
| Han, BR; Jung, HA; Jung, JY; Kim, HJ; Kim, HY; Zang, DY | 1 |
| Abou-Alfa, GK; Bekaii-Saab, TS; Bitzer, M; Borad, MJ; Borbath, I; El-Khoueiry, A; Goyal, L; Javle, M; Kelley, RK; Li, A; Macarulla, T; Moran, S; Pande, A; Philip, PA; Roychowdhury, S; Sadeghi, S; Shepherd, SP; Soifer, HS; Tanasanvimon, S; Waldschmidt, DT; Weiss, KH; Yong, WP; Zhu, AX | 1 |
| Cao, YB; Li, Q; Ma, YX; Sun, Y; Xu, CA; Zhang, XW | 1 |
| Xiao, J; Yu, H | 1 |
| Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A | 1 |
| Adam, AA; Allam, AH; Anderson, KI; Biankin, AV; Boulghourjian, A; Burgess, A; Chantrill, L; Chin, VT; Chou, A; Conway, JR; Cox, TR; Currey, N; Del Monte-Nieto, G; Drury, A; Evans, TR; Froio, D; Gallego-Ortega, D; Gill, AJ; Giry-Laterriere, M; Grey, ST; Harris, NL; Harvey, RP; Herrmann, D; Heu, C; Jain, R; Johns, AL; Kohonen-Corish, M; Lucas, MC; Magenau, A; McCloy, RA; McGhee, EJ; Melenec, P; Morton, JP; Nagrial, AM; Nobis, M; Ormandy, CJ; Pajic, M; Phan, T; Pinese, M; Samra, JS; Samuel, MS; Sansom, OJ; Steinmann, A; Timpson, P; Vennin, C; Walters, SN; Wang, Y; Warren, SC; Weninger, W; Whan, R; Zaratzian, A | 1 |
| Amada, K; Itoh, H; Nakahara, R; Ono, H; Sato, Y | 1 |
| Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM | 1 |
| Aono, T; Masuda, N; Matsunami, N; Mizutani, M; Nakayama, T; Nishida, Y; Ooe, A; Tanaka, S; Tanino, H; Tokunaga, S; Tsurutani, J; Tsuyuki, S; Yamaguchi, M; Yamamoto, D; Yamamura, J; Yasojima, H; Yoshidome, K | 1 |
| Arai, D; Chen, LT; Furuse, J; Ichikawa, W; Ikeda, M; Ioka, T; Ishii, H; Li, CP; Matsuyama, Y; Mizuno, N; Oh, DY; Okusaka, T; Park, YS; Ueno, M; Yamaguchi, T | 1 |
| Adamska, A; Domenichini, A; Falasca, M | 1 |
| Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O | 1 |
| Anders, RA; Che, X; Chen, J; Jaffee, EM; Kleponis, J; Muth, S; Rucki, AA; Sharma, R; Xiao, Q; Zheng, L | 1 |
| Chalchal, H; Payette, E; Sarker, S | 1 |
| He, X; Hu, C; Ou, D; Wu, M | 1 |
| Bianco, C; Bianco, R; Marciano, R; Servetto, A | 1 |
| Wang, X; Xiao, G; Yu, Y | 1 |
| Wang, J; Wang, M; Wang, Z; Yang, Y; Zheng, R; Zou, W | 1 |
| Ahn, C; Cheedella, N; Choy, H; Dowell, JE; Gerber, DE; Hughes, RS; Iyengar, P; Nedzi, L; Pulipparacharuvil, S; Timmerman, RD; Tumati, V; Wardak, Z; Westover, KD | 1 |
| Nunes, AA; Pereira, LRL; Peria, FM; Ungari, AQ | 1 |
| Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, YH; Sohn, JH | 1 |
| Bodis, S; Clavien, PA; Datta, NR; Khan, S; Knuchel, J; Mamot, C; Pestalozzi, B; Puric, E; Reiner, CS; Riesterer, O; Siebenhüner, A | 1 |
| Jensen, AB; Knoop, A; Langkjer, ST; Rosvig, LH | 1 |
| Chen, P; Chen, Q; Dong, R; Drisko, JA; Fan, F; Godwin, AK; Levine, M; Pessetto, Z; Polireddy, K; Reed, G; Violet, PC; Williamson, S; Yu, J | 1 |
| Klang, E; Lawson, P; Michal Amitai, M; Yonat, H | 1 |
| Akers, N; Albany, C; Bhardwaj, N; Chen, R; Domingo-Domenech, J; Donovan, MJ; Fleming, MT; Galsky, MD; Gnjatic, S; Hahn, NM; Hauke, RJ; Kim-Schulze, S; Losic, B; Oh, WK; Pal, SK; Patel, VG; Schadt, EE; Sfakianos, JP; Sonpavde, G; Starodub, A; Twardowski, P; Uzilov, AV; Wang, H; Yu, M; Zhao, Q | 1 |
| Gourd, E | 1 |
| Chung, V; Cristea, M; Diamond, DJ; Ellenhorn, JDI; Eng, M; Frankel, P; Hardwick, NR; Kaltcheva, T; Kilpatrick, J; Kos, F; Leong, L; Morgan, R; Ruel, C; Tinsley, R; Tsai, W; Wilczynski, S | 1 |
| Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H | 1 |
| Arun, B; Buzdar, AU; Hortobagyi, GN; Moulder, SL; Murray, JL; Murthy, RK; Shroff, GS; Stalzer, CJ; Szklaruk, J; Valero, V; Yam, C; Yang, W | 1 |
| Feng, M; Hu, Y; Huang, H; Xiong, G; Yang, G; You, L; Zhang, T; Zhao, Y; Zheng, L; Zheng, S | 1 |
| Dorjee, P; Long, ZW | 1 |
| Endo, T; Ikeda, A; Kandori, S; Kawai, K; Kojima, T; Kurobe, M; Miyagawa, T; Nishiyama, H; Tsutsumi, M; Uchida, M | 1 |
| Cao, J; Jiang, T; Luo, G; Qiu, Z; Wang, X; Xia, X; Zhang, K; Zhao, Q | 1 |
| Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K | 1 |
| Bianchi, G; Capri, G; Cona, MS; de Braud, F; Ferrari, B; Huber, V; Maggi, C; Manoukian, S; Mariani, G; Mennitto, A; Milano, M; Prisciandaro, M; Rinaldi, L; Rivoltini, L; Vernieri, C | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 1 |
| Goto, R; Hattori, M; Iwata, H; Kashiwaba, M; Kondo, N | 1 |
| Benson, AB; Catalano, PJ; Lubner, SJ; Menge, MR; Munshi, HG; Nimeiri, HS; O'Dwyer, PJ; Sahai, V; Zalupski, MM | 1 |
| Gou, H; Yi, C; Zhao, Y; Zhu, H | 1 |
| Gao, D; Qian, SY; Xu, Y; Yang, L; Yang, X | 1 |
| Choi, JH; Choi, YH; Huh, G; Kim, YT; Lee, SH; Paik, WH; Ryu, JK; You, MS | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Zhang, Z | 1 |
| Adeva, J; Alés-Díaz, I; Buxò, E; Cañabate, M; Carmona-Bayonas, A; De la Cámara, J; Fernández, A; Gallardo, E; Gallego, J; García, A; González, P; Guillén, C; Jiménez-Fonseca, P; Llorca, C; López, C; López, LJ; Muñoz, A; Navarro-Pérez, V; Pazo-Cid, RA; Quintero, G; Ramírez, P; Reboredo, M; Ruiz-Miravet, N; Salgado, M; Sanchez-Cánovas, M; Vera, R | 1 |
| Choi, YJ; Kang, EJ; Kim, DS; Kim, HJ; Kim, JS; Lee, SY; Seo, HY | 1 |
| Al-Muderis, O; Antoniou, G; Benson, C; Constantinidou, A; Jones, RL; Messiou, C; Miah, A; Petruckevitch, A; Sebio, A; Thway, K; VAN DER Graaf, WT; Zaidi, S | 1 |
| Ehrlich, A; Foerster, F; Galle, PR; Maderer, A; Marquardt, JU; Moehler, M; Nickolay, T; Ruckes, C; Schad, A; Sivanathan, V; Thomaidis, T; Weinmann, A; Woerns, M | 1 |
| Bryant, M; Davis, MJ; Hendifar, A; Hoffman, D; Jamil, L; Kim, S; Klempner, SJ; Lo, S; Nissen, N; Noe, P; Osipov, A; Piantadosi, S; Placencio-Hickok, V; Ristow, L; Rokhsar, S; Sandler, H; Scher, K; Shiao, SL; Tighiouart, M; Tuli, R; Wachsman, A | 1 |
| Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Kawaguchi, K; Kiyuna, T; Kumamoto, T; Li, Y; Matsuyama, R; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z | 1 |
| Cui, SH; Fu, Y; Sun, J; Wang, JC; Yang, D; Zhang, HT; Zhang, Q | 1 |
| Cao, F; Cao, Y; Fang, F; Jia, Z; Ju, X; Qing, S; Shen, Y; Zhang, H; Zhu, X | 1 |
| Jiménez Gordo, AM; López Gómez, M | 1 |
| Ishizuka, Y; Nakamichi, H; Sasano, T; Shiokawa, M; Tokou, U; Tsuji, D; Yabe, K; Yamamoto, K; Yoneda, T | 1 |
| Choi, HJ; Hong, JH; Jang, JS; Kang, JH; Kim, MJ; Kim, S; Kim, ST; Lee, HW; Lee, J; Lee, MA; Lim, HY; Oh, SY; Park, JO; Park, YS; Sohn, BS; Yoon, SY | 1 |
| Bekaii-Saab, T | 2 |
| Le Tourneau, C; Ricci, F | 1 |
| Higashi, T; Matsumoto, H; Nagatsu, K; Oe, Y; Sugyo, A; Tsuji, AB; Yoshii, Y; Yoshimoto, M; Zhang, MR | 1 |
| Guo, JC; Li, BQ; Liang, ZY; Liu, QF; Seery, S; You, L; Zhang, TP; Zhao, YP | 1 |
| Ding, H; Hu, X; Li, R; Tao, R; Tian, S; Wang, S; Wang, T | 1 |
| Alhothali, M; Chellappan, S; Iyer, G; Lawrence, HR; Mathew, M; Padmanabhan, J; Yang, S | 1 |
| Bynon, JS; Cen, P; Dinh, BC; Gonzalez, A; Mohlere, V; Thosani, NC; Wray, CJ; Zhang, S | 1 |
| Chen, C; Chen, H; Chen, Y; Lu, Y; Luo, Z; Peng, J; Wang, Z; Xu, D; Yin, P; Zheng, M | 1 |
| Alba, E; Awada, A; Bonnefoi, H; Charpentier, E; Coudert, B; Diéras, V; Emmons, GT; Garcia-Ribas, I; Gligorov, J; Jager, A; Lindeman, GJ; Paridaens, R; Pivot, X; Verweij, J; Zambelli, S | 1 |
| Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T | 1 |
| Ma, J; Sun, Y; Zhang, Y | 1 |
| Bang, K; Chang, HM; Hwang, I; Jeong, JH; Kim, KP; Kim, MH; Lee, K; Lee, SK; Lee, SS; Oh, D; Park, DH; Park, JH; Ryoo, BY; Song, TJ; Yoo, C | 1 |
| Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH | 1 |
| Kawakita, M; Matsumoto, K; Muguruma, K; Segawa, T; Sumiyoshi, T; Utsunomiya, N | 1 |
| Bednar, F; Heidt, DG; Lee, CJ; Li, C; Proctor, E; Simeone, DM; Waghray, M; Yalamanchili, M | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Baba, H; Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fukutomi, A; Funakoshi, A; Furuse, J; Hatori, T; Ikeda, M; Ioka, T; Kitano, M; Mizumoto, K; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Shimamura, T; Sho, M; Sugimori, K; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K; Yanagimoto, H | 1 |
| Chen, G; Cui, QC; Du, X; Shi, J; Shu, H; Wang, TX; You, L; Zhang, TP; Zhao, YP; Zhou, L | 1 |
| Beets, GL; Beets-Tan, RG; Breukink, SO; Dejong, CH; Engelen, SM; Jansen, RL; Lahaye, MJ; Leijtens, JW; Maas, M; van Berlo, CL; van de Velde, CJ | 1 |
| El Mahdy, MM; El-Arab, LR; Swellam, M | 1 |
| Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M | 1 |
| Al-Batran, SE; Bichev, D; Haller, B; Homann, N; Lordick, F; Lorenzen, S; Luley, K; Pauligk, C; Schumacher, G; Schuster, T; Thuss-Patience, P | 1 |
| Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ | 1 |
| Benhadji, KA; Makiuchi, T; Nokihara, H; Sekiguchi, R; Slapak, CA; Tamura, T; Uenaka, K; Yamada, Y; Yamamoto, N | 1 |
| Assadourian, S; Barone, C; Hatteville, L; Humblet, Y; Karasek, P; Manges, R; Philip, PA; Riess, H; Rougier, P; Santoro, A | 1 |
| Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA | 1 |
| Artru, P; Bachet, JB; Bidard, FC; Bouché, O; Chibaudel, B; Desseigne, F; Hammel, P; Huguet, F; Louvet, C; Mathiot, C; Mineur, L; Pierga, JY | 1 |
| Lv, X; Pan, ZH; Su, A; Zhang, J; Zhou, QM | 1 |
| Chauffert, B; Ghiringhelli, F; Wiazzane, N | 1 |
| Badola, S; Chen, L; Deng, H; Fuchs, CS; Gansert, JL; Kindler, HL; Loh, E; McCaffery, I; Patterson, SD; Suzuki, S; Tang, R; Tudor, Y | 1 |
| Fu, Z; Wang, X; Yin, H; Zhang, X | 1 |
| Chan, A; Conte, PF; Espie, M; Ganju, V; Gil, MG; Llombart, A; Majois, F; Petruzelka, L; Tubiana-Mathieu, N; Vaissiere, N; Villanova, G | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW | 1 |
| Ball, D; Collins, M; Francis, H; Franco, M; Kofoed, S; Mileshkin, L; Paramanathan, A; Solomon, B | 1 |
| Hansen, TF; Jakobsen, A; Nielsen, BS; Sørensen, FB | 1 |
| Jarboe, J; Saif, MW | 1 |
| Bachelot, T; Blasinska-Morawiec, M; Capitain, O; Cognetti, F; Crown, JP; Davidson, N; Diéras, V; Fasching, PA; Fountzilas, G; Greil, R; Huang, X; Kern, KA; Kreienberg, R; Liedtke, C; Miller, WH; Paolini, J; Ramos, M; Romieu, G; Staroslawska, E; Tassell, V; Wildiers, H; Yardley, DA | 1 |
| Boisen, MK; Dehlendorff, C; Hansen, J; Hansen, TF; Holländer, NH; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Nielsen, SE; Pfeiffer, P; Tarpgaard, LS; Østerlind, K | 1 |
| Chao, Y; Lee, RC; Lee, WP; Li, CP; Wang, JP; Wu, CY | 1 |
| Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW | 1 |
| Chen, Q; Hu, H; Jiao, D; Song, J; Wu, L; Xu, LQ; Yan, J | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Ohsumi, S; Takabatake, D; Takahashi, M; Takashima, S; Watanabe, M | 1 |
| Centeno, BA; Chellappan, SP; Lawrence, NJ; Pernazza, D; Pillai, S; Sebti, SM; Singh, S; Treviño, JG; Verma, M; Zhang, D | 1 |
| Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC | 1 |
| Baba, H; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Mochiki, E; Okada, N; Tajima, Y; Yokoyama, M | 1 |
| Giessen, C; Graeven, U; Hegewisch-Becker, S; Heinemann, V; Laubender, RP; Modest, DP; Porschen, R; Reinacher-Schick, A; Schmiegel, W; Schulz, C; Stintzing, S | 1 |
| Bai, L; Jiao, SC; Li, J; Long, YY; Shi, WW; Su, D; Wang, LJ | 1 |
| Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU | 1 |
| Chi, HD; Liu, Z; Orlando, M; Quinlivan, M; Xu, B; Zhang, XQ | 1 |
| Burdaeva, O; Chang, JC; Kirby, MG; Rivera, E; Semiglazov, V; Spector, T | 1 |
| Baek, JY; Chang, HJ; Kim, DY; Kim, MJ; Kim, SY; Kim, TH; Lee, SU; Oh, JH; Park, JW | 1 |
| Saif, MW | 1 |
| Forgeson, G; Prince, SK | 1 |
| Allen, A; Andersson, R; Bassi, C; Boeck, S; Bondar, V; Bondarenko, I; Davidenko, I; Dicker, A; Evans, TR; Garin, A; Hahn, H; Heinemann, V; Ikdahl, T; Isaacson, J; Kaur, P; Mann, E; Ormanns, S; Picozzi, V; Poplin, E; Raponi, M; Rolfe, L; Voong, C; Wasan, H | 1 |
| Kautio, AL; Kellokumpu-Lehtinen, PL; Lehtinen, I; Tanner, M; Tuunanen, T | 1 |
| Abbott, DE; Abbruzzese, JL; Aloia, TA; Crane, CH; Evans, DB; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Tran Cao, HS; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Fujisawa, M; Inoue, T; Miyake, H; Miyazaki, A; Tanaka, H; Terakawa, T; Yokoyama, N | 1 |
| Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N | 1 |
| Blakely, LJ; Houts, AC; Schwartzberg, LS; Somer, BG; Stepanski, EJ; Walker, MS; Wang, G; Wheeler, BM | 1 |
| Chiba, S; Hori, Y; Shimizu, K | 1 |
| Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G | 1 |
| Bestoso, E; Bianco, MT; Botta, C; Caraglia, M; Ciliberto, D; Conca, R; Correale, P; Cusi, MG; Fioravanti, A; Guglielmo, A; Guidelli, GM; Licchetta, A; Mantovani, G; Martino, E; Mini, E; Misso, G; Pastina, P; Pirtoli, L; Ridolfi, R; Rotundo, MS; Tagliaferri, P; Tassone, P | 1 |
| Azemoto, R; Hara, T; Hirata, N; Ishihara, T; Mikata, R; Nakagawa, A; Nakaji, S; Nakamura, K; Nihei, T; Nishino, T; Ohshima, T; Ozawa, F; Shimura, K; Sudo, K; Tada, M; Tawada, K; Yamaguchi, T; Yokosuka, O | 1 |
| Chang, H; Chen, L; Du, XJ; Gao, YH; Liu, MZ; Peng, HH; Wen, BX; Xiao, L; You, KY; Zeng, ZF; Zhou, GQ | 1 |
| Fan, Y; Li, J; Liao, Y; Peng, L; Wan, Y | 1 |
| Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D | 1 |
| Ahn, JS; Chang, W; Choi, MK; Im, SA; Im, YH; Kim, S; Lee, SY; Park, YH; Woo, SY | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W | 1 |
| Kita, I; Mukubo, H; Nakanuma, S; Sato, N; Takanaka, T; Yasui, T | 1 |
| Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Arrowsmith, E; Austin, T; Beckman, R; Forero-Torres, A; Greenberg, J; Hart, L; He, AR; Infante, JR; Jin, X; Rosen, M; Saleh, M; Trent, D; Vickers, S; von Roemeling, R; Wade, J; Wang, Q; Waterhouse, D; Wong, L | 1 |
| Ghosh, S; Loree, JM; Mulder, KE; Spratlin, JL | 1 |
| Gonda, T; Halmos, B; Melamed, J; Miller, G; Rotterdam, H; Seetharamu, N; Villanueva, G | 1 |
| Berthou, J; Bichard, D; Borg, C; Facy, O; Ghiringhelli, F; Heyd, B; Ladoire, S; Lakkis, Z; Limat, S; Lorgis, V; Nerich, V; Orry, D; Ortega-Deballon, P; Rat, P; Vincent, J | 1 |
| Benzon, EV; Brünner, N; Christensen, IJ; Engelmann, BE; Gerds, TA; Hansson, SH; Holländer, NH; Højgaard, L; Kjær, A; Kristensen, MH; Löfgren, J; Loft, A; Markova, E; Nielsen, HJ; Sloth, C | 1 |
| Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q | 1 |
| Braun, JJ; de Graaf, H; de Groot, SM; de Jongh, FE; Hamaker, ME; Los, M; Maartense, E; Nortier, JWR; Seynaeve, C; Smorenburg, CH; van Leeuwen-Stok, AE; van Tinteren, H; Wymenga, AN | 1 |
| Albertsson, M; Holmqvist, A; Miger, J; Sun, XF | 1 |
| Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL | 1 |
| Bai, LY; Chao, Y; Chen, JS; Hsieh, JS; Li, CP; Su, WC; Su, YC; Tai, CJ; Wu, CC; Yeh, HT; Yeh, KH | 1 |
| Cartwright, T; Cassidy, J; Chu, E; Haller, D; Lee, S; McKenna, E; Saif, MW; Schmoll, HJ; Sun, W; Twelves, C | 1 |
| Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC | 1 |
| Al-Batran, SE; Gencer, D; Hartmann, JT; Hochhaus, A; Hofheinz, RD; Kripp, M; Merx, K; Miranda, MB | 1 |
| Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G | 1 |
| Aksun, S; Alacacioglu, A; Bayoglu, IV; Coban, E; Demir, L; Dirican, A; Kucukzeybek, Y; Sutcu, R; Tarhan, MO; Varol, U | 1 |
| Jia, Y; Marks, E; Saif, MW | 1 |
| Amoroso, V; Berruti, A; Biasco, G; Birocco, N; Bodei, L; Brizzi, MP; D'Avolio, A; Dogliotti, L; Fazio, N; Ferrero, A; Nobili, E; Papotti, M; Priola, AM; Torta, M; Tozzi, L; Volante, M | 1 |
| Ciftci, R; Disci, R; Duranyildiz, D; Karabulut, S; Sakar, B; Sen, F; Tas, F | 1 |
| Benson, AB; Gates, VL; Habib, A; Hickey, R; Kircher, S; Lewandowski, RJ; Mulcahy, MF; Newman, S; Nimeiri, H; Salem, R; Vouche, M | 1 |
| Ahn, JB; Baek, SJ; Baik, SH; Cho, MS; Chung, M; Hur, H; Kim, CW; Kim, MS; Kim, NK; Min, BS; Shin, SJ | 1 |
| Berlin, JD; Pauff, JM; Thota, R | 1 |
| Ashihara, K; Fujiwara, S; Kanemura, M; Kawaguchi, H; Ohmichi, M; Sasaki, H; Takai, M; Tanabe, A; Tanaka, T; Tanaka, Y; Terai, Y; Tsunetoh, S | 1 |
| Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J | 1 |
| Guillen-Ponce, C; Molina-Garrido, MJ; Mora-Rufete, A | 1 |
| Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M | 1 |
| Boukovinas, I; Christophylakis, C; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Karampeazis, A; Matikas, A; Polyzos, A; Souglakos, J; Vamvakas, L | 1 |
| Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M | 1 |
| Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A | 1 |
| Arumugam, T; Elmetwally, AM; Lin, HY; Mousa, SA; Nazeer, T; Phillips, P; Sudha, T; Yalcin, M | 1 |
| Bockorny, B; Dasanu, CA | 1 |
| Barni, S; Blasi, L; Cinieri, S; Colucci, G; De Vita, F; Fedele, P; Filippelli, G; Gebbia, N; Giotta, F; Lorusso, V; Maiello, E; Orlando, L; Pappagallo, GL; Pisconti, S; Riccardi, F; Verderame, F | 1 |
| Gervasi, E; Giovanardi, F; Pezzuolo, D; Prati, G; Scaltriti, L; Scarabelli, L | 1 |
| Alonso, V; Alonso-Espinaco, V; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Gallego, R; Garcia-Albeniz, X; Horndler, C; Jares, P; Lozano, JJ; Marmol, M; Maurel, J; Ortego, J; Rosell, R | 1 |
| Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ | 1 |
| Balslev, E; Bartels, A; Bjerre, C; Bjerre, KD; Brünner, N; Ejlertsen, B; Jørgensen, CL; Nielsen, DL | 1 |
| Ahn, E; Ambros, T; Aruna, M; Kronish, L; Mahtani, RL; Montero, AJ; Vogel, CL; Zaravinos, J; Zeichner, SB | 1 |
| Abe, T; Ensako, T; Hino, K; Nakamura, M; Nakashima, H; Yoshida, K | 1 |
| Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E | 1 |
| Baker, AF; Bolejack, V; Burris, H; Crowley, J; Dayyani, F; Dragovich, T; Hidalgo, M; Laheru, D; Raghunand, N; Ritch, P; Rosen, P; Seng, J; Smith, L; Von Hoff, DD | 1 |
| Alishekevitz, D; Bril, R; Fremder, E; Gingis-Veltski, S; Hasnis, E; Karban, A; Raviv, Z; Shaked, Y; Voloshin, T | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Joka, M; Krause, A; Licht, T; Seufferlein, T; Wichert, Gv; Zech, CJ | 1 |
| Agarwal, N; Apolo, AB; Galsky, MD; Gimpel-Tetra, K; Godbold, JH; Lee, KM; Lowe, N; Oh, WK; Poole, A; Soto, R; Tsao, CK | 1 |
| Brekken, RA; Carroll, KD; Cenik, BK; Hagopian, MM; Nugent, D; Ostapoff, KT; Rivera, LB; Topalovski, M; Wang, M; Xu, X; Ye, R | 1 |
| Carter, GC; Johnson, BH; Landsman-Blumberg, PB; Li, L; Nicol, SJ; Sedgley, R; Shankaran, V | 1 |
| Hirano, T; Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
| Huber, K; Saif, MW; Yu, E | 1 |
| Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK | 1 |
| Brammer, M; Guardino, E; Guerin, A; Hurvitz, S; Lalla, D; Latremouille Viau, D; Wu, EQ; Zhou, ZY | 1 |
| Hirai, K; Igarashi, T; Miyamae, Y; Ogawa, H; Sunose, Y; Takahashi, K; Takahashi, N; Takeyoshi, I; Tanaka, K; Tsukagoshi, H; Yoshinari, D | 1 |
| Barlesi, F; Besse, B; Cappuzzo, F; Carcereny, E; Felip, E; Ferry, D; Garcia-Ribas, I; Mazieres, J; Novello, S; Reck, M; Santoro, A; Scagliotti, G; Soria, JC; von Pawel, J; Zalcman, G | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Fuereder, T; Hoeflmayer, D; Kornek, G; Kuehrer, I; Scheithauer, W; Stift, J; Stranzl, N | 1 |
| Chen, LH; Liu, TF; Liu, XF; Sun, JQ; Yang, H; Yin, C; Zhang, H | 1 |
| Chen, XZ; Jin, T; Li, B | 1 |
| Han, L; Li, W; Liu, J; Ma, J; Ma, Q; Reindl, KM; Wang, F; Wu, E; Wu, Z; Zhang, D | 1 |
| Aprile, G; Ciuleanu, T; Csutor, Z; Federowicz, I; Fittipaldo, A; Hsu, C; Klughammer, B; Li, CP; Lipp, R; Meng, X; Moore, M; Nowara, E; Stemmer, SM; Tham, CK; Van Cutsem, E; Van Laethem, JL; Zeaiter, A | 1 |
| Chen, K; Gumireddy, K; Huang, Q; Li, A; Li, H; Tang, K; Wang, J; Xiao, H; Xiao, W; Xu, H; Yao, W; Ye, Z; Yu, G | 1 |
| Asano, E; Funasaka, K; Goto, H; Hamaguchi, M; Hirooka, Y; Hyodo, T; Miyahara, R; Senga, T; Wong, M | 1 |
| Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI | 1 |
| Abel, EV; Balis, UG; Blau, JL; Craig, R; Greenson, JK; Griffith, KA; Khan, GN; Kim, EJ; Sahai, V; Simeone, DM; Takebe, N; Zalupski, MM | 1 |
| Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B | 1 |
| Chen, JS; Chou, WC; Hsu, HC; Huang, WK; Kuo, YC; Shen, WC; Tsang, NM; Yang, TS | 1 |
| Awada, A; Cortes, J; He, Y; Kaufman, PA; Olivo, M; Twelves, C; Vahdat, L | 1 |
| Bouvet, M; Endo, I; Fleming, JB; Hiroshima, Y; Hoffman, RM; Katz, MH; Maawy, AA | 1 |
| Agelaki, S; Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mavroudis, D; Vamvakas, L; Vardakis, N | 1 |
| Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
| Agarwal, N; Bellmunt, J; Di Lorenzo, G; Eigl, BJ; Giannatempo, P; Hussain, SA; Locke, J; Necchi, A; Niegisch, G; Pal, SK; Pond, GR; Poole, A; Singh, P; Sonpavde, G; Vaishampayan, UN | 1 |
| Bergaglio, M; Buonerba, C; Calabrese, F; Damiano, V; De Maio, AP; Di Lorenzo, G; Federico, P; Lalle, M; Marino, M; Merola, C; Milella, M; Montella, L; Ottaviano, M; Palmieri, G; Von Arx, C | 1 |
| Eustermann, H; Harich, HD; Hinke, A; Jackisch, C; Reichert, D; Schoenegg, W; Selbach, J; Tesch, H; Welslau, M; Wohlfarth, T | 1 |
| Friedrich, M; Kummer, S; Terjung, A | 1 |
| Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X | 1 |
| Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD | 1 |
| Aksoy, A; Arpaci, E; Bahceci, A; Bayoglu, IV; Besiroglu, M; Dane, F; Duran, AO; Hacibekiroglu, I; Inanc, M; Karaca, H; Menekse, S; Ozkan, M; Sevinc, A; Tanriverdi, O; Uysal, M; Yapici, HS; Yazilitas, D | 1 |
| Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R | 1 |
| Carlsen, AL; Hansen, TF; Heegaard, NH; Jakobsen, A; Sørensen, FB | 1 |
| Beuzeboc, P; Chevreau, C; Culine, S; Dupuy, L; Filleron, T; Fléchon, A; Gravis, G; Houédé, N; Laguerre, B; Théodore, C | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G | 2 |
| Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY | 1 |
| Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY | 1 |
| Aboagye, EO; Barwick, T; Challapalli, A; Howell, EC; Mauri, F; Maxwell, RJ; Merchant, S; Pearson, RA; Sharma, R; Sumpter, K | 1 |
| Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH | 1 |
| Beijnen, JH; Boot, H; Cats, A; Cerny, TD; Doodeman, VD; Huitema, AD; Joerger, M; Meijerman, I; Meulendijks, D; Rosing, H; Schellens, JH; Smits, PH; Vainchtein, L; Zueger, M | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Bakkum-Gamez, JN; Behbakht, K; Hensley, ML; Mannel, RS; Michael, H; Miller, A; O'Malley, DM | 1 |
| Abali, H; Köse, F; Mertsoylu, H; Muallaoğlu, S; Ozyilkan, O; Sezer, A; Sümbül, AT | 1 |
| Abe, H; Horie, S; Ide, H; Isotani, S; Kamai, T; Kitamura, K; Muto, S; Noguchi, T; Sugiura, S; Yamaguchi, R | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Nagashima, A; Ohkubo, Y; Shimokawa, R; Suzuki, Y; Yamamuro, W; Yoneda, M | 1 |
| Collins, DC; Morris, PG | 1 |
| Abraham, I; Bootman, JL; Gharaibeh, M; McBride, A | 1 |
| Anthony, S; Babiker, HM; Borad, MJ; Buchbinder, A; Grem, J; Keilani, T; Mita, M | 1 |
| Motoi, F; Unno, M | 1 |
| Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J | 1 |
| Baba, H; Egawa, N; Fukutomi, A; Funakoshi, A; Hamada, C; Hamamoto, Y; Hosotani, R; Hyodo, I; Ichikawa, Y; Ikeda, M; Isayama, H; Ishii, H; Matsumoto, S; Nagase, M; Nakamori, S; Ohkawa, S; Okusaka, T; Omuro, Y; Sho, M; Takahashi, S; Tsuchiya, Y; Tsuda, M; Unno, M; Wakabayashi, G; Watanabe, G; Yamada, N; Yamaguchi, K; Yanagimoto, H | 1 |
| Abeni, C; Aroldi, F; Bertocchi, P; Di Biasi, B; Meriggi, F; Ogliosi, C; Rizzi, A; Rosso, E; Rota, L; Savelli, G; Zaniboni, A | 1 |
| Bria, E; Cognetti, F; Garufi, C; Melisi, D; Milella, M; Nuzzo, C; Reni, M; Scarpa, A; Sperduti, I; Tortora, G; Vaccaro, V; Vari, S | 1 |
| Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC | 1 |
| Benedit, P; Carrato, A; García, P; Gostkorzewicz, J; López, R; Macarulla, T; Pérez-Alcántara, F; Rivera, F; Sastre, J | 1 |
| Baba, E; Iguchi, A; Kusaba, H; Sagara, K; Sakamoto, N; Takayoshi, K; Uchino, K | 1 |
| Cerezuela Fuentes, P; Ferris Villanueva, E; García Márquez, A; Guerrero Bautista, R; Martínez Penella, M; Mira Sirvent, Mdel C | 1 |
| Cohen, RB; Doroumian, S; LoRusso, PM; Morris, JC; Olowokure, OO; Olszanski, AJ; Puzanov, I; Rixe, O; Shen, L; Yin, JY | 1 |
| Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Jung, SH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH; Woo, SY | 1 |
| Chang, YF; Chen, SY; Hsiao, CH; Hsieh, JC; Hsieh, RK; Hsu, CL; Lee, KD; Lu, CH; Ng, SH; Shiau, CY; Wang, CH; Wang, HM; Yeh, KH | 1 |
| Atkins, MB; Choueiri, TK; McDermott, DF; McKay, RR; Michaelson, MD; Olivier, KM; Signoretti, S; Song, J; Van Allen, EM; Werner, L | 1 |
| Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I | 1 |
| Anderson, K; Au, A; Bailey, P; Biankin, A; Carter, CR; Chang, D; Erler, JT; Evans, TR; Jamieson, NB; Karim, S; Leach, J; Marais, R; McGarry, L; McGhee, E; McKay, C; Miller, BW; Morton, JP; Oien, K; Pinese, M; Sansom, OJ; Saturno, G; Shanks, E; Springer, C; Steele, C; Timpson, P | 1 |
| Gu, MF; Li, JJ; Li, Y; Li, YQ; Liu, LZ; Pan, K; Shen, WX; Xia, JC; Zhang, H | 1 |
| Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T | 1 |
| Aieta, M; Angelini, V; Antonuzzo, L; Azzarello, D; Bertolini, A; Corsi, DC; Di Costanzo, F; Di Fabio, F; Giommoni, E; Latiano, T; Mogavero, S; Pastina, I; Pastorelli, D; Pavese, I; Pazzagli, M | 1 |
| Belfiore, G; Belfiore, MP; De Lucia, G; Di Gennaro, TL; Gallo, C; Ianniello, GP; Marsicano, C; Romano, F; Ronza, FM | 1 |
| Asadi, K; Chionh, F; Lee, CK; Mariadason, JM; Murone, C; Nagtegaal, ID; Parry, MM; Price, TJ; Punt, CJ; Scott, AM; Simes, J; Tebbutt, NC; Weickhardt, AJ; Williams, DS; Wilson, K | 1 |
| Amano, H; Ikeda, Y; Ito, H; Kainuma, M; Miura, F; Sano, K; Shibuya, M; Takada, T; Toyota, N; Wada, K | 1 |
| Lv, W; Wu, XZ; Yan, T; Zhang, JH; Zhang, WL | 1 |
| Brachmann, CB; Heise, C; Hidalgo, M; Illei, P; Lopez-Casas, PP; Lopez-Rios, F; Menendez, C; Musteanu, M; Pierce, D; Plaza, C; Romano, A; Tabernero, J; Von Hoff, DD; Wei, X | 1 |
| Chu, GC; Chung, LW; Li, Q; Shi, C; Wu, JB; Xu, Q; Yu, JS; Zhang, Y; Zhau, HE | 1 |
| Bassett, R; Champlin, R; Gulbis, AM; Holmberg, L; Jones, RB; Kingham, A; Ledesma, C; Margolin, K; Nieto, Y; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Brekken, RA; Dellinger, MT; Dineen, SP; Haaland, G; Kirane, A; Lorens, JB; Ludwig, KF; Micklem, D; Ranaweera, R; Sandal, T; Sorrelle, N; Toombs, JE; Wang, M | 1 |
| Doi, T; Fuse, N; Hynes, SM; Lin, AB; Matsubara, N; Naito, Y; Nakamura, T; Shitara, K; Uenaka, K; Yoshino, T | 1 |
| Arbaud, C; Bachet, JB; Bidault, AT; Bonnetain, F; Coriat, R; Dahan, L; de la Fouchardière, C; Dréanic, J; Dubreuil, O; Hammel, P; Lecomte, T; Lepère, C; Locher, C; Marthey, L; Pernot, S; Portal, A; Taieb, J; Tchoundjeu, B; Tougeron, D | 1 |
| André, T; Bachet, JB; Bonnetain, F; Chibaudel, B; Hammel, P; Louvet, C; Validire, P | 1 |
| Fukunaga, M; Hasegawa, J; Hazama, S; Kono, E; Kotaka, M; Maeda, H; Mishima, H; Nagata, N; Oba, K; Sakamoto, J; Soda, H; Takahashi, T | 1 |
| Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y | 1 |
| Guo, J; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM | 1 |
| Bourade, V; Chen, E; Doyle, L; Goel, R; Halford, R; Jonker, D; Keller, D; Laurie, SA; Lheureux, S; Oza, AM; Siu, LL; Wang, L | 1 |
| Carstens, JL; Kalluri, R; Kaye, J; Kim, J; LeBleu, VS; Scheible, M; Sugimoto, H; Wu, CC; Zheng, X | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Allavena, P; Belli, C; Cangi, MG; Cappio, S; Ceraulo, D; D'Incalci, M; Doglioni, C; Dugnani, E; Garassini, G; Maggiora, P; Piemonti, L; Porcu, L; Reni, M; Zucchetti, M | 1 |
| Behrns, KE; Black, BS; Delitto, D; George, TJ; Han, S; Hughes, SJ; Knowlton, AE; Liu, C; Lu, X; Sarosi, GA; Thomas, RM; Trevino, JG; Vlada, AC; Wallet, SM; Zhang, D | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Boegemann, M; Krabbe, LM; Schlack, K; Schrader, AJ; Steinestel, J | 1 |
| Arena, F; Goldstein, D; Korn, RL; Liu, H; Lu, B; McGovern, D; Moore, M; Ramanathan, RK; Siena, S; Tabernero, J; Teixeira, L; Van Laethem, JL; Von Hoff, DD | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nakajima, TE; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Cao, L; Chen, L; Hu, X; Liu, M; Yao, G; Ye, C | 1 |
| Cheng, Y; Guo, Y; Ma, L; Xiong, BH; Zhang, T | 1 |
| Adachi, S; Doi, S; Hirose, Y; Iwashita, T; Kawaguchi, J; Kozawa, O; Moriwaki, H; Nakashima, M; Okuno, M; Shimizu, M; Yasuda, I; Yoshimi, N | 1 |
| Beare, S; Bridgewater, J; Duggan, M; Lee, D; Lopes, A; McEntee, D; Ricamara, M; Sukumaran, A; Valle, JW; Wasan, H | 1 |
| Boeck, S; Haas, M; Heinemann, V; Kruger, S; Westphalen, CB | 1 |
| Chayahara, N; Imamura, Y; Kiyota, N; Kotake, T; Minami, H; Mukohara, T; Nishimura, M; Saito, K; Saito, Y; Takenaka, K; Toyoda, M; Tsuji, A | 1 |
| Bailey, P; Balkwill, F; Barry, ST; Biankin, AV; Bryson, S; Candido, JB; Carter, CR; Chang, DK; Clarke, M; Connelly, J; Eberlein, C; Evans, TRJ; Foth, M; Jamieson, N; Karim, SA; Leach, JDG; McDaid, K; Morton, JP; Nibbs, RJB; Nixon, C; Rishi, L; Sansom, OJ; Steele, CW; Strathdee, D; Upstill-Goddard, R; Wilson, Z | 1 |
| Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S | 1 |
| Aroldi, F; Bertocchi, P; Fraccon, AP; Mutti, S; Prochilo, T; Rizzi, A; Savelli, G; Zaniboni, A | 1 |
| Han, SM; Han, Y; Shi, SB; Tian, J; Wang, YS | 1 |
| Doihara, H; Iwamoto, T; Matsuoka, J; Mitsuhashi, T; Mizoo, T; Motoki, T; Nogami, T; Ogasawara, Y; Shien, T; Taira, N; Tsuji, H; Yoshitomi, S | 1 |
| Bellmunt, J; Galsky, MD; Giannatempo, P; Grivas, P; Necchi, A; Pond, GR; Raggi, D; Sonpavde, G; Vogelzang, NJ | 1 |
| Chiorean, EG; El-Maraghi, R; Goldstein, D; Harris, M; Li, JS; Liu, H; Lu, B; Ma, WW; Manax, V; Reni, M; Romano, A; Tabernero, J; Von Hoff, DD; Whorf, R | 1 |
| Anamalai, M; Julka, PK; Kumaran, D; Nambirajan, A; Velu, U | 1 |
| Biederman, L; Blanco, F; Brody, JR; Jimbo, M; Jing, Y; Londin, E; Rigoutsos, I; Telonis, AG; Xia, NL; Zhou, H | 1 |
| Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S | 1 |
| Chen, LT; Hsu, MC; Hung, WC; Luo, CW; Pan, MR; Shan, YS | 1 |
| DeCaire, X; Streu, E | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Ciardiello, F; Conzo, G; De Vita, F; Diana, A; Fabozzi, A; Febbraro, A; Galizia, G; Giordano, G; Laterza, MM; Orditura, M; Petrillo, A; Savastano, B; Troiani, T; Ventriglia, J | 1 |
| Adamson, DJ; Arif, SS; Bidoli, P; Carroll, KJ; Chang, D; Cheeseman, S; Dalgleish, AG; Diaz-Beveridge, R; Fernandez-Martos, C; Gaya, A; Glynne-Jones, R; Granetto, C; Martín, AJ; Massuti, B; McAdam, K; McDermott, R; Mudan, SS; Papamichael, D; Pazo-Cid, R; Stebbing, J; Vieitez, JM; Wagle, S; Zaniboni, A | 1 |
| Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, Y; Yu, S; Yu, YY; Zhao, NQ; Zhuang, RY | 1 |
| Bahary, N; Hogg, ME; Poruk, KE; Steve, J; Weiss, MJ; Wolfgang, CL; Wright, GP; Zeh, HJ; Zenati, MS; Zuriekat, AH | 1 |
| Dan, G; Deng, D; Jiang, J; Li, W; Zheng, X; Zheng, Y | 1 |
| Esumi, H; Fujioka, R; Hasegawa, H; Hashimoto, Y; Ikeda, M; Kishino, S; Mitsunaga, S; Miyoshi, C; Mochizuki, N; Nomura, S; Ohno, I; Sato, A; Takahashi, H; Takahashi, R; Toyosaki, K; Tsuchihara, K; Yomoda, S | 1 |
| Bastuji-Garin, S; Brureau, L; Canoui-Poitrine, F; Carvahlo-Verlinde, M; Culine, S; Demery, ME; Fléchon, A; Laurent, M; Paillaud, E; Thuaut, AL | 1 |
| Li, JS; McGovern, D; Romano, A; Römmler-Zehrer, J; Stahl, M; Vogel, A | 1 |
| Ferrara, S; Goldstein, D; Kunzmann, V; Liu, H; Lu, B; Ramanathan, RK; Renschler, MF; Von Hoff, DD | 1 |
| Agarwal, N; Alva, A; Bamias, A; Bellmunt, J; Casey, MF; Crabb, SJ; De Giorgi, U; Galsky, MD; Harshman, LC; Ladoire, S; Necchi, A; Niegisch, G; Pal, SK; Powles, T; Ramos, JD; Recine, F; Rosenberg, JE; Vaishampayan, UN; Wong, YN; Yu, EY | 1 |
| Agarwal, N; Agarwal, P; Baisre, A; Goldstein, IM; Hansberry, DR; Kavi, A | 1 |
| Hara, I; Iba, A; Kikkawa, K; Kodama, Y; Kohjimoto, Y; Matsumura, N; Nakamura, Y; Nishizawa, S | 1 |
| Han, SS; Hong, EK; Joo, J; Kim, MK; Kim, TH; Kim, YH; Kong, SY; Lee, JH; Lee, WJ; Moon, H; Park, B; Park, SJ; Woo, SM; Yoon, KA | 1 |
| Ahn, MJ; Bello, M; Cho, EK; Depenbrock, H; Orlando, M; Park, K; Puri, T; Soldatenkova, V; Song, EK; Thongprasert, S | 1 |
| Han, X; Lu, N; Pan, Y; Xu, J | 1 |
| Akiyama, Y; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Morimoto, Y; Murakami, K; Naito, A; Ohmura, Y; Oneda, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Araki, H; Choda, Y; Harano, M; Idani, H; Ishida, M; Kanazawa, T; Matsukawa, H; Mimura, N; Ninomiya, M; Ogawa, T; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Sumitani, D | 1 |
| Altan, B; Araki, K; Hosouchi, Y; Ishii, N; Kubo, N; Kuwano, H; Nishiyama, M; Shirabe, K; Suzuki, H; Tsukagoshi, M; Watanabe, A; Yokobori, T | 1 |
| Duan, Q; Li, H; Shen, Q; Wang, C; Wu, H; Yin, T; Zhang, Z; Zhao, H | 1 |
| Agelaki, S; Agelidou, A; Boukovinas, I; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, A; Mavroudis, D; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Grossbard, ML; Kozuch, P; Nieto, J | 1 |
| Fasching, PA; Heinemann, V; Kalischefski, B; Kolbl, H; Laessig, D; Maubach, P; Meerpohl, H; Melchert, F; Morack, G; Scharl, A; Stauch, M; Stemmler, HJ; Vehling-Kaiser, U; Weber, B | 1 |
| Cassidy, J | 1 |
| Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T | 1 |
| Batista, N; Cruz, J; Dómine, M; Estévez, LG; León, A; Provencio, M; Rodríguez, M; Sánchez-Rovira, P; Velasco, A | 1 |
| Asmar, L; Boehm, KA; Doane, L; Loesch, D; McIntyre, K; Monticelli, M; O'Shaughnessy, JA; Orlando, M; Paul, D; Vaughn, LG; Vukelja, S; Zhan, F | 1 |
| Bennouna, J; Douillard, JY; Senellart, H | 1 |
| Aziz, R; Booth, B; Bullock, J; Dagher, R; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kasliwal, R; Lechleider, RJ; Leighton, J; Pazdur, R; Pope, S; Sridhara, R | 1 |
| Jonasch, E; Mathew, P; Ng, CS; Pagliaro, L; Siefker-Radtke, A; Tannir, NM; Thall, PF; Wang, X; Wood, C; Wooten, L | 1 |
| Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY | 1 |
| Bunnell, C; Gralow, J; Klimovsky, J; Peck, R; Poulart, V; Schwartzberg, L; Thomas, E; Vahdat, L | 1 |
| Abali, H; Budakoglu, B; Hayran, M; Oksuzoglu, B; Yildirim, N; Zengin, N | 1 |
| Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M | 1 |
| Andreetta, C; Damante, G; Di Loreto, C; Fasola, G; Minisini, A; Pandolfi, M; Pegolo, E; Piga, A; Pizzolitto, S; Puglisi, F; Puppin, C; Valent, F | 1 |
| Amendt, C; Bruns, CJ; Eichhorn, ME; Ischenko, I; Jauch, KW; Kleespies, A; Mantell, O; Seeliger, H | 1 |
| Bosnjak, SM; Radulovic, S; Susnjar, S | 1 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| Aerts, R; Bielen, D; Budiharto, T; Ectors, N; Goethals, L; Haustermans, K; Topal, B; Van Cutsem, E; Van Steenbergen, W; Vanbeckevoort, D; Verslype, C | 1 |
| Bergsland, EK; Hwang, J; Ko, AH; Tempero, MA; Venook, AP; Wong, D | 1 |
| Cianfrocca, M | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R | 1 |
| Almhanna, K; Kim, R | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Huh, JW; Jung, EJ; Kwon, JE; Lee, KY; Park, YA; Sohn, SK | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Narita, S; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Yuasa, T | 1 |
| Amadori, D; Cecconetto, L; Dall'agata, M; Dazzi, C; Frassineti, GL; Milandri, C; Nanni, O; Oliverio, G; Pasquini, E; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Fujisawa, M; Gleave, ME; Hayashi, N; Miyake, H; Muramaki, M; So, A; Sowery, R | 1 |
| Hamada, K; Horiuchi, R; Igarashi, R; Obayashi, K; Ohwada, S; Sunose, Y; Takeyoshi, I; Yamamoto, K | 1 |
| Dobrova, NV; Lichinitser, MR; Semenov, NN; Vakhabova, JV | 1 |
| Beck, AW; Brekken, RA; Carbon, JG; Dineen, SP; Mamluk, R; Miller, AF; Sullivan, LA; Wong, H | 1 |
| Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J | 1 |
| Bayo, J; Bernabé, R; Fernández, A; Fernández-Freire, A; Fuentes, J; Lomas, M; Moreno, A; Rodríguez, A; Ruiz, M; Salvador, J | 1 |
| Yardley, DA | 3 |
| Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M | 1 |
| Bane, CL; Gross, GG; LaPlant, BR; Palmieri, FM; Roy, V | 1 |
| Hay, JW; Le, QA | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Jeong, CY; Ju, JH; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Kim, TH; Lee, GW | 1 |
| Bucci, L; Cannella, L; Carlomagno, C; D'Armiento, FP; D'Armiento, MR; De Placido, S; De Stefano, A; Farella, A; Pacelli, R; Pepe, S; Pesce, G; Solla, R | 1 |
| Boehnke Michaud, L | 1 |
| Abramo, F; Lorenzo, RM; Marconato, L; Ratto, A; Zini, E | 1 |
| Brandely, M; Crivellari, D; Foa, P; Fougeray, R; Goldhirsch, A; Mattioli, R; Nolè, F; Pinotti, G; Verri, E | 1 |
| Antonini, NF; Cats, A; Creemers, GJ; Dalesio, O; Dijkstra, JR; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Richel, DJ; Rodenburg, CJ; Schrama, JG; Sinnige, HA; Tol, J; van Groeningen, CJ; van Krieken, JH; Vink-Börger, ME; Voest, EE; Vos, AH | 1 |
| Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK | 1 |
| Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A | 1 |
| Hirohata, S; Horita, K; Niki, T; Nishisaki, H; Tsuda, M; Yamamoto, Y | 1 |
| Foo, KF; Wang, ML | 1 |
| An, GL; Gu, SZ; Li, XH; Lian, JW; Pan, BR; Qin, TJ; Tian, F; Zhao, XH | 1 |
| Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ | 1 |
| Aprile, G; Mazzer, M; Moroso, S; Puglisi, F | 1 |
| Casaretti, R; Comella, P; de Portu, S; Franco, L; Menditto, E | 1 |
| Li, J; Saif, MW | 1 |
| Dollinger, MM; Endlicher, E; Fuchs, M; Gäbele, E; Harder, J; Hinke, A; Hollerbach, C; Hollerbach, S; Kullmann, F; Messmann, H; Trojan, J | 1 |
| Bennouna, J; Cosaert, J; Gill, S; Humblet, Y; Moore, MJ; Scheithauer, W; Shang, A; Van Cutsem, E; Van Laethem, JL; Verslype, C; Vervenne, WL | 1 |
| Albain, KS; Bayer, R; Chew, HK; Doroshow, JH; Frankel, P; Gandara, DR; Gordon, M; Hantel, A; Lenz, HJ; Margolin, KA; Russell, C; Somlo, G; Spicer, D; Stiff, PJ; Synold, T; Tetef, ML; Yang, D; Zhang, W | 1 |
| Ch'ang, HJ; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Huang, CL; Hwang, TL; Jan, CM; Lin, JT; Shiah, HS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| Chow, WA; Doroshow, JH; Frankel, P; Gandara, DR; Lenz, HJ; Leong, LA; Lim, D; Margolin, KA; Morgan, RJ; Newman, EM; Shibata, SI; Somlo, G; Synold, TW; Yen, Y | 1 |
| Filip, S; Finek, J; Holubec, L; Kormunda, S; Kozevnikova, R; Pavlikova, I; Sediva, M; Sefrhansova, L; Svoboda, T; Votavova, M | 1 |
| Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA | 1 |
| Des Guetz, G; Morere, JF; Nicolas, P; Schischmanoff, O; Uzzan, B | 1 |
| Baracos, VE; Koski, S; Mackey, JR; McCargar, LJ; Mourtzakis, M; Pituskin, E; Prado, CM; Reiman, T; Sawyer, MB; Tonkin, K | 1 |
| Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X | 1 |
| Alacacioglu, A; Erten, C; Meydan, N; Somali, I; Tarhan, MO; Usalp, S; Yilmaz, U | 1 |
| Haller, DG; Teitelbaum, UR | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Brunetti, IM; Bursi, S; Chiara, S; Cupini, S; Di Donato, S; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Cohen, HJ; Dressler, LG; Gralow, JR; Grenier, D; Hart, RD; Hudis, CA; Kartcheske, PA; Kornblith, AB; Magrinat, G; Mahmood, AA; Mauer, AM; Muss, HB; Norton, L; Parker, BA; Partridge, AH; Perez, EA; Theodoulou, M; Wheeler, JD; Winer, EP; Wolff, AC | 1 |
| Goff, LW; Mernaugh, RL; Pohlmann, PR | 1 |
| Di Maio, M; Falcone, A; Loupakis, F | 1 |
| Copur, MS; Norvell, M; Obermiller, A | 1 |
| Arima, K; Hasegawa, Y; Kise, H; Nishikawa, K; Soga, N; Sugimura, Y; Yamada, Y | 1 |
| Inaba, T; Kashiwaba, M; Komatsu, H; Takeda, Y; Takiyama, I; Tomisawa, Y; Wakabayashi, G | 1 |
| Fukuda, T; Shiroiwa, T; Tsutani, K | 1 |
| Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY | 1 |
| Hanahan, D; Olson, P | 1 |
| Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M | 1 |
| Kim, SN; Lee, KS; Nam, BH; Park, IH; Ro, J; Yun, YH | 1 |
| Dong, N; Jiang, W; Li, H; Liu, Z; Wang, M; Xu, X | 1 |
| Becquart, D; Bougnoux, P; Chan, A; Conte, PF; Espie, M; Majois, F; Morand, M; Tubiana-Mathieu, N; Vaissiere, N; Villanova, G | 1 |
| Dreisbach, L; Kristedja, T; Kurtin, S; Mahadevan, D; Obregon, Y; Von Hoff, DD; Williams, D | 1 |
| Canil, C; Dent, SF; Gertler, S; Goel, R; Iscoe, N; Keller, O; Segal, R; Verma, S; Young, V | 1 |
| Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF | 1 |
| Aggarwal, BB; Anand, P; Deorukhkar, A; Diagaradjane, P; Gelovani, J; Guha, S; Harikumar, KB; Krishnan, S; Kunnumakkara, AB; Kuzhuvelil, HB | 1 |
| Saltz, LB; Segal, NH | 1 |
| Aogi, K; Horikoshi, N; Kimura, M; Kusama, M; Miura, S; Noguchi, S; Nomizu, T; Shin, E; Tabei, T; Toyama, K; Yoshimoto, M; Yoshimura, N | 1 |
| Altintas, S; Huizing, MT; Specenier, PM; Van den Brande, J; Van den Weyngaert, D; Van Laer, C; Vermorken, JB; Weyler, J | 1 |
| Guan, Y; He, J; Jiang, M; Shao, W; Tucker, S; Wang, D; Wu, Y; Xu, X; Yang, H; Ying, W; Zhong, B; Zhong, N | 1 |
| Jones, A; Nowara, E; O'Brien, M; Perraud, K; Pham, ML; Pienkowski, T; Rolski, J; Sommer, H; Trillet-Lenoir, V; Welt, A | 1 |
| Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J | 1 |
| Amadori, D; Aquilina, M; Cecconetto, L; Ibrahim, T; Maltoni, R; Massa, I; Nanni, O; Passardi, A; Pietri, E; Ridolfi, R; Rocca, A; Sarti, S | 1 |
| Chan, D; Chuah, B; Goh, BC; Lee, SC; Lim, SE; Soo, R; Tan, SH; Tiemsim Cordero, M; Wong, CI; Yeo, WL | 1 |
| Asmar, L; Becerra, C; Boehm, KA; Gersh, RH; Gill, JF; Hozak, RR; Kuefler, PR; Mullaney, BP; Myrand, SP; Nicol, SJ; Obasaju, CK; Richards, DA; Wilfong, LS; Zhan, F; Zhao, L | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Hagihara, A; Hashimoto, K; Ikeda, M; Kojima, Y; Kondo, S; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L | 1 |
| Kaley, K; Peccerillo, J; Saadati, H; Saif, MW; Schilsky, ML | 1 |
| Garcia-Alfonso, P; Gonzalez-Flores, E; Mendez-Ureña, M; Muñoz-Martin, A; Perez-Manga, G; Quiben-Pereira, R | 1 |
| Cathomas, R; Köberle, D; Mayer, G; Mey, U; Räss, A; Ruhstaller, T; von Moos, R | 1 |
| Bartsch, R; Brodowicz, T; Gerges, DA; Inbar, M; Pawlega, J; Spanik, S; Timcheva, C; Tomova, A; Tzekova, V; Wiltschke, C; Zielinski, CC | 1 |
| Kellokumpu-Lehtinen, PL; Koskinen, S; Sunela, KL | 1 |
| Koopman, M; Punt, CJ | 1 |
| Chen, XQ; He, YJ; Li, YH; Luo, HY; Qiu, MZ; Shi, YX; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| Esser, N; Graeser, R; Jantscheff, P; Kluth, J; Massing, U; Sukolinskaya, A; Taylor, LA; Unger, C; Ziroli, V | 1 |
| Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N | 1 |
| Clegg, A; Cooper, K; Jones, J; Loveman, E; Takeda, A; Tan, SC | 1 |
| Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T | 1 |
| Blackwelder, WC; Chawla, SP; Chua, VS; Fernandez, L; Gordon, EM; Hall, FL; Quon, D | 1 |
| Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A | 1 |
| Bergaglio, M; Ceribelli, A; De Placido, S; Del Prete, S; Di Lorenzo, G; Federico, P; Lalle, M; Marino, M; Merola, C; Merola, G; Milella, M; Montella, L; Palmieri, G; Petillo, L | 1 |
| Bentzen, L; Buch-Hansen, TZ; Hansen, S; Hoeyer, M; Jensen, NV; Saxe, C; Sengeloev, L | 1 |
| Chyi Lee, F; Fekrazad, HM; Rabinowitz, I; Royce, M; Smith, HO; Verschraegen, CF | 1 |
| Dentchev, T; Dueck, AC; Fitch, TR; Geeraerts, LH; Graham, DL; Gross, HM; Hillman, DW; Kahanic, SP; Le-Lindqwister, NA; Liu, H; Palmieri, FM; Patel, TA; Perez, EA | 1 |
| Behl, S; Behrens, R; Buechner-Steudel, P; Fahlke, J; Fleig, WE; Kleber, G; Kuss, O; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Capelozzi, VL; Galvão, FH; Pestana, JO | 1 |
| Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C | 1 |
| Adema, AD; Fichtner, I; Laan, AC; Myhren, F; Peters, GJ; Sandvold, ML; Verheul, HM | 1 |
| Antoniani, B; Bepler, G; Boulware, D; Cognetti, F; Fabi, A; Lara Rivera, S; Metro, G; Monteiro, AN; Mottolese, M; Schell, M; Vici, P; Zheng, Z | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, C; Kim, TW; Lee, JL; Lim, HY; Park, YS; Ryoo, BY; Ryu, MH | 1 |
| Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R | 1 |
| Georgoulias, V; Mauri, D; Mavroudis, D; Patsopoulos, NA; Polyzos, NP; Valachis, A | 1 |
| Anan, K; Masuda, N; Mitsuyama, S; Nishimura, R; Ohno, S; Takamatsu, Y; Tamura, K; Tanaka, M; Yamamoto, Y | 1 |
| Bae, SH; Chae, YS; Choi, GS; Jun, SH; Kang, BW; Kim, JG; Kim, NS; Moon, JH; Park, JH; Park, JY; Ryoo, HM; Sohn, SK | 1 |
| Gridelli, C; Pallis, AG | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K | 1 |
| Andersen, RF; Brandslund, I; Garm Spindler, KL; Hansen, TF; Jakobsen, A; Lindebjerg, J | 1 |
| Ferraz, MB; Puga, ME; Riera, R; Soárez, PC | 1 |
| Albrecht, H; Boxberger, F; Hahn, EG; Hohenberger, W; Konturek, PC; Männlein, G; Ostermeier, N; Reulbach, U; Roehrig, S; Wein, A; Wolff, K | 1 |
| Ashley, S; Cunningham, D; Okines, AF | 1 |
| Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA | 1 |
| Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY | 1 |
| Best, JH; Garrison, LP | 1 |
| Ashley, S; Johnston, S; Kotsori, AA; Noble, JL; Smith, IE | 1 |
| Chung, EK; Hahn, OM; Karrison, T; Kasza, K; Manchen, E; Posadas, EM; Stadler, WM | 1 |
| Moore, M; Renouf, D | 1 |
| Farhat, FS; Ghosn, MG; Kattan, J | 1 |
| Davis, TH; Dragnev, KH; Hardin, SB; Pipas, JM; Rigas, JR | 1 |
| Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y | 1 |
| Kawaguchisakita, N; Kohno, Y; Tsubota, Y; Tsuyuki, S; Ukikusa, M | 1 |
| Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE | 1 |
| Boku, N; Doi, T; Hamamoto, Y; Kato, K; Koizumi, W; Komatsu, Y; Mizunuma, N; Muro, K; Sato, A; Takiuchi, H; Yamaguchi, K | 2 |
| Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M | 1 |
| Adansa, JC; Cruz, JJ; Gil-Arnaiz, I; Hitt, R; Irigoyen, A; Isla, D; Lambea, J; Lecumberri, MJ; Martinez-Trufero, J | 1 |
| Fan, Y; Wang, J; Xu, B | 1 |
| Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D | 1 |
| Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L | 1 |
| Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B | 1 |
| Pownall, M | 1 |
| Aggarwal, S; Goel, G; Jauhri, M; Negi, A | 1 |
| Mallmann, P; Nitschmann, S | 1 |
| Foster, J; Lee, J; Urba, S; Worden, F; Zhang, J | 1 |
| An, X; Ding, PR; He, YJ; Jiang, WQ; Li, YH; Shi, YX; Wang, FH; Wang, ZQ; Xu, RH | 1 |
| Bouvet, M; Fruehauf, J; Hoffman, RM; Imagawa, DK; Katz, MH; Kaushal, S; Keleman, A; Kim, G; Romney, E; Tran Cao, HS | 1 |
| Aogi, K; Fujimoto, T; Funai, J; Kamigaki, S; Okazaki, M; Saeki, T; Sagara, Y; Takashima, S; Toi, M; Yoshida, M | 1 |
| Berglund, A; Brünner, N; Christensen, IJ; Frederiksen, C; Glimelius, B; Jensen, BV; Keldsen, N; Nielsen, HJ; Nielsen, SE; Pfeiffer, P; Qvortrup, C | 1 |
| Bisht, S; Chenna, V; Feldmann, G; Goggins, MG; Hong, SM; Karikari, C; Maitra, A; Mizuma, M; Ottenhof, NA; Pramanik, D; Ravi, R; Rudek, MA; Sharma, R | 1 |
| Chitapanarux, I; Hsieh, CY; Kamnerdsupaphon, P; Lertsanguansinchai, P; Lorvidhaya, V; Phromratanapongse, P; Sukthomya, V; Tharavichitkul, E | 1 |
| Anton, A; Bermejo, B; Casado, A; Gayo, J; Lao, J; Lluch, A; Martin, M; Muñoz, M; Paules, AB; Provencio, M | 1 |
| Buti, S; Caminiti, C; Chiesa, MD; Donini, M; Lazzarelli, S; Lheshi, A; Mattioli, R; Mazza, G; Passalacqua, R; Re, GL; Simon, S; Simonelli, C | 1 |
| Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T | 1 |
| Bassett, MR; Bedolla, G; Campbell, AD; Davis, AT; Koo, HM; Luttenton, CR; Melnik, MK; Monroe, TJ; O'Rourke, TJ; Richardson, PJ; Stein, P; Szczepanek, CM; Truszkowski, KJ; Van Brocklin, MW; Vande Woude, GF; Webb, CP; Yost, KJ | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Fotiou, S; Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Ahn, MJ; Do, IG; Ko, YH; Park, K; Park, YH; Won, YW | 1 |
| Ahn, JS; Ahn, YC; Cho, EY; Im, YH; Kim, K; Kim, KH; Lee, S; Park, K; Park, YH; Shim, YM | 1 |
| Cai, R; Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W | 1 |
| Bult, P; van Herpen, CM; van Laarhoven, HW; Wesseling, P; Willemsen, AE | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH | 1 |
| Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K | 1 |
| Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR | 1 |
| Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I | 1 |
| Fornier, M | 1 |
| Cartwright, T; Chu, E; McKenna, EF; Schulman, KL | 1 |
| Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F | 1 |
| Carlson, D; Fury, MG; Haque, S; Pfister, D; Shen, R; Stambuk, H | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Hutson, TE; Shepard, D | 1 |
| Backer, JM; Backer, MV; Buhr, HJ; Hotz, B; Hotz, HG | 1 |
| Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V | 1 |
| Fan, J; Ling, W; Ma, Y; Wang, H | 1 |
| Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE | 1 |
| Abajo, A; Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Ponz, M; Rodriguez, J; Zarate, R | 1 |
| Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N | 1 |
| Iwase, S; Kitamura, K; Kuroda, Y; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D; Yoshida, H | 1 |
| Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M | 1 |
| Blum, JL; Glück, S; Hu, S; Kaye, JA; Kohles, J; McKenna, E; Odom, D; Scotto, N | 1 |
| Gelderblom, H; Guchelaar, HJ; Pander, J; Punt, CJA; van der Straaten, T; Wessels, JAM | 1 |
| Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, SF; Messersmith, WA; Spigel, DR; Weekes, CD; Yardley, DA | 1 |
| Boban, M; Hrabar, A; Omrčen, T; Vrdoljak, E | 1 |
| Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L | 1 |
| Ayuso, D; Becht, C; Culine, S; Huguet, H; Iborra, F; Pouessel, D; Rebillard, X | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Han, SS; Hong, EK; Kim, DY; Kim, SH; Kim, TH; Lee, WJ; Moon, SH; Park, JW; Park, SJ; Woo, SM; Yoo, T | 1 |
| Hassan, M; Osman, MM | 1 |
| Ahn, JS; Cho, EY; Choi, YL; Im, YH; Kim, ST; Lee, SJ; Park, YH | 1 |
| Bachelot, T; Biron, P; Blay, JY; Favier, B; Galy, G; Guastalla, JP; Labidi-Galy, SI; Latour, JF; Perol, D; Ray-Coquard, I; Tredan, O | 1 |
| Bradley, C; Koo, IC; O'Shaughnessy, J; Osborne, C; Patt, D; Pippen, JE; Rocha, C; Sherman, BM; Yoffe, M | 1 |
| Chen, D; Chen, DS; Cobleigh, MA; Harris, AL; Hillan, KJ; Jubb, AM; Koeppen, H; Langmuir, VK; Miller, KD; Reimann, JD; Rugo, HS; Schmidt, M | 1 |
| Kamimura, K; Kojima, K; Mizutani, M; Shioiri, M; Watanabe, Y; Yamamoto, S | 1 |
| Ng, S; O'bichere, A; Platell, C; Tebbutt, N | 1 |
| Jiang, Z; Lu, X; Shen, G; Song, S; Wang, T; Wu, S; Zeng, M; Zhang, S | 1 |
| Brito, LG; de Andrade, JM; Lins-Almeida, T; Marana, HR; Peria, FM; Pinheiro, MN; Tiezzi, DG; Zola, FE | 1 |
| Caparro, M; Giantonio, B; Haller, DG; Mykulowycz, K; O'Dwyer, PJ; Olthoff, K; Reddy, R; Rosen, M; Shaked, A; Sohal, D; Soulen, MC; Sun, W; Teitelbaum, UR | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS | 1 |
| Boban, M; Boskovic, L; Fridl-Vidas, V; Hrepic, D; Omrcen, T; Vrdoljak, E | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 1 |
| Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F | 1 |
| Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C | 1 |
| Atkinson, BJ; Byfield, SD; Feng, C; Jonasch, E; Lal, LS; Miller, LA; Pagliaro, LC; Tannir, NM | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| Demidov, L; Galchenko, V; Kharkevich, G; Naidzionak, U; Petenko, N; Sinelnikov, I; Tsimafeyeu, I | 1 |
| Davies, JM; Farrugia, D; Hayward, N; Kirichek, O; Medley, L; Morel, AN; Reed, N; Talbot, DC; Thakker, RV | 1 |
| Feigin, K; Gajria, D; Geneus, S; Hudis, CA; Norton, L; Patil, S; Tan, LK; Theodoulou, M; Traina, TA | 1 |
| Cabebe, EC; Fisher, GA; Sikic, BI | 1 |
| Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY | 1 |
| Abenhardt, W; Brudler, O; Brugger, W; diGioia, D; Freier, W; Gitsch, G; Heinemann, V; Hurtz, HJ; Jonat, W; Kettner, E; Rösel, S; Stemmler, HJ; Tesch, H; Tessen, HW | 1 |
| Abt, M; Burns, I; Chen, E; Goldstein, D; Major, P; McKendrick, J; Rittweger, K; Robinson, B; Zhi, J | 1 |
| Backshall, A; Clarke, SJ; Keun, HC; Sharma, R | 1 |
| El-Khoueiry, AB; Gandara, D; Lenz, HJ; Ramanathan, RK; Shibata, S; Wright, JJ; Yang, DY; Zhang, W | 1 |
| Gilbar, P; Sorour, N | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Bruno, R; Claret, L; Frances, N; Iliadis, A | 1 |
| Abbruzzese, JL; Bennett, B; Bullock, S; Cunningham, P; Fogelman, D; Jafari, M; Lin, E; Morris, J; Ozer, H; Varadhachary, GR; Wolff, RA; Xiong, H | 1 |
| Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C | 1 |
| Bertucci, F; Esterni, B; Extra, JM; Gilabert, M; Gonçalves, A; Jacquemier, J; Madroszyk, A; Tarpin, C; Viens, P | 1 |
| Collins, IM; Thomas, DM | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C | 1 |
| Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M | 1 |
| Adler, M; Dörken, B; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Stieler, J | 1 |
| Alvarez, RH; Hortobagyi, GN; Valero, V | 1 |
| Hara, I; Matsumura, N | 1 |
| Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L | 1 |
| Bell, JA; Conte, P; Corey-Lisle, PK; Hortobagyi, G; Mukhopadhyay, P; Orsini, L; Peck, R; Revicki, DA; Roche, H; Safikhani, S | 1 |
| Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Danso-Appiah, A; Eastwood, A; Norman, G; Palmer, S; Rice, S; Spackman, E; Stirk, L; Suh, D | 1 |
| Arkenau, HT; Baraniskin, A; Graeven, U; Meier, D; Munding, J; Porschen, R; Reinacher-Schick, A; Schmiegel, W; Schulmann, K; Tannapfel, A | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Ballal, S; Dicke, K; Gurtler, J; Katz, T; Kayaleh, O; Keaton, M; Ko, AH; Lenz, HJ; Rowinsky, EK; Youssoufian, H | 1 |
| Cheng, CY; Cherng, SH; Huang, XY; Liao, FT; Sheu, GT; Wu, MF; Wu, WJ; Yang, TY | 1 |
| Iwaki, R; Motohiro, T; Oishi, M; Yamamichi, K; Yoh, T | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Hoshino, K; Ide, H; Masuda, T; Satou, A; Tasaka, Y; Uchida, Y; Yasumizu, Y | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O | 1 |
| Beck, T; Bromund, J; Brufsky, A; Frontiera, M; Hainsworth, J; Hoelzer, K; Keaton, M; Krill-Jackson, E; Kroener, J; Marciniak, MD; Middleman, E; Nadella, P; Obasaju, C; Orlando, M; Panella, T; Paul, D; Tai, F; Whorf, R; Zhao, L | 1 |
| Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K | 1 |
| Calvani, N; Cinefra, M; Cinieri, S; Fedele, P; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Adenis, A; Boige, V; Boucher, E; Chauffert, B; Conroy, T; Cvitkovic, F; Ducreux, M; Farace, F; François, E; Galais, MP; Guichard, P; Jacques, N; Malka, D; Pierga, JY; Vimond, N | 1 |
| Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA | 1 |
| Blum, JL; Hennessy, BT; Leonard, R; O'Shaughnessy, J | 1 |
| Ando, M; Hirohata, M; Imagawa, A; Kato, H; Kawamoto, H; Matsumoto, K; Miyake, Y; Nakatsu, M; Toyokawa, T; Yamamoto, K | 1 |
| Doihara, H; Ikeda, H; Masuda, H; Nishiyama, K; Nogami, T; Shien, T; Taira, N | 1 |
| Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Dosch, J; Hynes, M; Li, C; Pasca di Magliano, M; Sarkar, B; Simeone, DM; Welling, TH; Wu, JJ | 1 |
| Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z | 1 |
| Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T | 1 |
| Ball, D; Burmeister, BH; Burmeister, E; Cox, S; Forouzesh, B; Horwood, K; Lehman, M; Michael, M; Sasso, G; Wirth, A | 1 |
| Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I | 1 |
| Alexandre, J; Bachelot, T; Bourgeois, H; de Rauglaudre, G; Hardy-Bessard, AC; Jaubert, D; Largillier, R; Lortholary, A; Paraiso, D | 1 |
| Cetina, L; Coronel, J; Dueñas-Gonzalez, A | 1 |
| Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ | 1 |
| Borad, MJ; Desai, N; Hidalgo, M; Iglesias, JL; Korn, RL; Laheru, DA; Maitra, A; Rajeshkumar, NV; Ramanathan, RK; Shi, T; Smith, LS; Soon-Shiong, P; Trieu, V; Von Hoff, DD; Wood, TE; Zhang, H | 1 |
| Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W | 1 |
| Brostjan, C; Brugger, P; Gnant, M; Kuehrer, I; Reiter, C; Schauer, D; Schoppmann, SF; Sommerfeldt, S; Starlinger, P; Tamandl, D | 1 |
| Assenat, E; Bleuse, JP; Mazard, T; Pinguet, F; Portales, F; Poujol, S; Samalin, E; Thezenas, S; Thirion, A; Ychou, M | 1 |
| Bonneterre, J; Bourbouloux, E; Campone, M; Fumoleau, P; Isambert, N; Milano, G; Roché, H | 1 |
| Aggarwal, BB; Park, B; Prasad, S; Sung, B; Yadav, V | 1 |
| Kotek, A; Parlak, C; Pehlivan, B; Topkan, E; Yapar, AF | 1 |
| Chua, DT; Hong, RL; Krishnan, G; Kurnianda, J; Ng, AW; Ng, WT; Seetalarom, K; Shotelersuk, K; Sze, WK; Wang, CH; Yang, MH; Yiu, HH | 1 |
| Andersson, M; Bjerre, KD; Cold, S; Jakobsen, EH; Jørgensen, CL; Kamby, C; Møller, S; Nielsen, DL; Stenbygaard, L; Sørensen, PG | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Asmis, TR; Hilton, JF; Jonker, DJ; Moore, MJ; O'Callaghan, CJ; Parulekar, W; Powell, ED; Tu, D; Vickers, MM | 1 |
| Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM | 1 |
| Costantini, C; Millard, F | 1 |
| Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ | 1 |
| Fukuta, F; Kunishima, Y; Kyoda, Y | 1 |
| Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM | 1 |
| Kato, K | 1 |
| Abad, A; Antón, A; Aranda, E; Arrivi, A; Benavides, M; Cervantes, A; Díaz-Rubio, E; Dueñas, R; Escudero, P; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Lacasta, A; Llanos, M; López-Ladrón, A; Losa, F; Marcuello, E; Martínez de Prado, P; Massutí, B; Rivera, F; Safont, MJ; Sastre, J; Tabernero, JM; Valladares, M | 1 |
| Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, Ch; Makrantonakis, P; Polyzos, A; Souglakos, J; Vamvakas, L; Xynogalos, S; Ziras, N | 1 |
| Martin, M; Miles, D; Robert, N; Vrdoljak, E; Zielinski, C | 1 |
| Bazzan, AJ; Deshmukh, S; Levine, M; Littman, S; Mitchell, E; Monti, DA; Newberg, AB; Pillai, MV; Yeo, CJ; Zabrecky, G | 1 |
| Abe, M; Demizu, Y; Fujii, O; Hashimoto, N; Hishikawa, Y; Jin, D; Kitajima, N; Mima, M; Murakami, M; Niwa, Y; Sasaki, R; Sirakawa, S; Sugimura, K; Takatori, K; Terashima, K; Yonson, K | 1 |
| Cui, Y; Dong, N; Guo, Q; Li, H; Wang, M | 1 |
| Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V | 1 |
| Feng, XZ; Han, JQ; Sheng, W | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Luini, A; Mancuso, P; Montagna, E; Pastrello, D; Sandri, MT | 1 |
| Georgoulias, V; Kalbakis, K; Karachaliou, N; Kouroussis, Ch; Mavroudis, D; Papakotoulas, P; Poppis, E; Tryfonidis, K; Vardakis, N | 1 |
| Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S | 1 |
| Chilelli, M; D'Auria, G; Fabbri, MA; Frittelli, P; Massari, A; Moscetti, L; Natoli, G; Nelli, F; Ruggeri, EM | 1 |
| O'Shaughnessy, JA; Perez, EA; Rugo, HS | 2 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K | 1 |
| Liu, BX; Ying, JE; Zhu, LM | 1 |
| Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J | 1 |
| Chahine, G; Farhat, F; Ghosn, M; Kattan, J; Nasr, F; Saroufim, A | 1 |
| Inoue, T; Kamba, T; Matsui, Y; Nishiyama, H; Ogawa, O; Saito, R; Sumiyoshi, T; Xing, ND; Yoshimura, K | 1 |
| Dalivoust, P; Debled, M; Harbeck, N; Kaufmann, M; O'Shaughnessy, JA; Robert, NJ; Siedentopf, F | 1 |
| Che, L; Di, L; Dong, N; Jia, J; Jiang, H; Ren, J; Song, G; Wang, C; Wang, X; Wang, Z; Yu, J; Zheng, X; Zhou, X; Zhu, B | 1 |
| Bao, Q; He, B; Pan, Y; Song, G; Tang, Z; Tian, F; Wang, S | 1 |
| Allred, JB; Bernath, AM; Fishkin, PA; Fitch, TR; Flynn, P; Perez, EA; Salim, M; Stella, PJ; Tan, WW; Wiesenfeld, M | 1 |
| Abdullah, M; Al Khodary, A; Barsoum, M; El Nowieam, S; El Zawahry, H; Gaafar, R; Gouda, Y; Halim, IA; Hamada, E; Hamid, TA; Kohail, H; Mansour, O; Meshref, M; Shehata, S; Taleb, FA; Wareth, AA | 1 |
| Colucci, G; Di Maio, M; Giuliani, F; Perrone, F | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S | 1 |
| Conibear, J; Raouf, S; Tarver, K | 1 |
| Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY | 1 |
| Altwegg, R; Assenat, E; Caillo, L; Faure, S; Flori, N; Guillaumon, V; Mazard, T; Samalin, E; Senesse, P; Thezenas, S; Ychou, M | 1 |
| Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G | 1 |
| Abe, C; Furusawa, H; Hirata, M; Kawaguchi, Y; Morita, S; Okamoto, Y; Sakamoto, J; Takami, M; Takao, S; Yamashita, S; Yoshimoto, M | 1 |
| Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Abad, A; Aranda, E; Arrivi, A; Benavides, M; Díaz-Rubio, E; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Maestro, ML; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Tabernero, JM; Valladares, M; Vidaurreta, M | 1 |
| Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC | 1 |
| Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M | 1 |
| Bosserman, L; Gómez, H; Li, RK; Manikhas, A; Medina, C; Mukhopadhyay, P; Opatt, D; Ro, J; Sparano, JA; Thomas, E; Vahdat, L; Valero, V; Vrdoljak, E; Xu, B | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Barlev, A; Bray, S; Butt, Z; Cella, D; Fuchs, CS; Kindler, HL; Oglesby, A | 1 |
| Arnold, D; Dellas, K; Dunst, J; Reese, T; Richter, M | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Bray, SL; Chan, D; Feigal, EG; Fuchs, CS; Galimi, F; Garbo, LE; Garon, EB; Hei, Y; Kindler, HL; Kocs, DM; Loh, E; McGreivy, J; Richards, DA; Rocha-Lima, CM; Safran, H; Stephenson, JJ | 1 |
| Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S | 1 |
| Bafaloukos, D; Economopoulos, T; Eleftheraki, AG; Fountzilas, G; Kalogeras, KT; Klouvas, G; Koutras, A; Makatsoris, T; Nikitas, N; Papakostas, P; Papandreou, CN; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Samantas, E; Sgouros, J; Syrigos, KN; Timotheadou, E; Varthalitis, I; Xanthakis, I | 1 |
| Bekaii-Saab, TS; Bloomston, M; Ellison, EC; Kleiber, B; Li, X; Martin, LK; Zalupski, M | 1 |
| Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J | 1 |
| Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R | 1 |
| Aguilella-Vizcaíno, MJ; Calleja-Hernández, MÁ; Cortés-Funes Castro, H; Cortijo-Cascajares, S; García-Escobar, I; Herreros-de-Tejada, A; Nacle-López, I | 1 |
| Duan, W; Li, X; Liu, H; Ma, Q; Wu, E; Xu, H | 1 |
| Jang, SJ; Kim, CW; Kim, JC; Kim, JH; Kim, TW; Kwak, JY; Lim, SB; Yu, CS | 1 |
| Bai, W; He, AR; Hwang, J; Marshall, J; Mikhail, S; Navarro, R; Pishvaian, M; Shivapurkar, N; Wellstein, A | 1 |
| Blay, JY; Bompas, E; Cioffi, A; Collin, F; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Isambert, N; Jimenez, M; Pautier, P; Penel, N; Piperno-Neumann, S; Rey, A | 1 |
| Azuma, K; Fukumoto, T; Kikugawa, T; Miura, N; Miyauchi, Y; Shimamoto, K; Shirato, A; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Ceruse, P; Fayette, J; Girodet, D; Péron, J; Poupart, M; Ramade, A; Zrounba, P | 1 |
| Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
| Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B | 1 |
| Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G | 1 |
| Frances, N; Iliadis, A; Marouani, H; Mercier, C; Woloch, C | 1 |
| Labianca, R; Merelli, B; Mosconi, S | 1 |
| Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V | 1 |
| Dimitroulis, D; Felekouras, E; Griniatsos, J; Karatzas, T; Karavokyros, J; Kontzoglou, K; Mantas, D; Nikiteas, N; Polyzos, A; Polyzos, K; Syrigos, K; Tsavaris, N; Vafiadis, I | 1 |
| Forssell, H; Krona, H; Pröh, K; Wester, M | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M | 1 |
| Liu, Y; Shen, H; Su, Z; Wang, D; Yin, R; Zhang, Z; Zhu, H; Zhu, Y | 1 |
| Arrowsmith, E; Beck, T; Borson, R; Bromund, J; Hager, S; Harker, G; Harrer, G; Horvath, W; Jones, M; Kornberg, LJ; Kudrik, FJ; Malamud, SC; Obasaju, C; Orlando, M; Reeves, J; Tai, DF; Tillinghast, G; Yardley, DA; Zeigler, H | 1 |
| Gan, Y; Gu, SY; Guo, HY; Hu, XC; Wang, BY; Wang, JL; Wang, LP; Wang, ZH; Zhang, J; Zhao, XM | 1 |
| de Braud, F; Díaz-Rubio, E; Pietrantonio, F | 1 |
| Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R | 1 |
| Hwang, YI; Jang, SH; Jung, KS; Kim, DG; Kim, JH; Kim, SY; Park, S | 1 |
| Avancha, K; Glück, S; Lopes, G; Montero, AJ | 1 |
| Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J | 1 |
| Meng, L; Wang, Y; Wei, JF; Yang, H | 1 |
| Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A | 1 |
| Boettcher, M; Eisen, C; Fredebohm, J; Gaida, MM; Giese, NA; Greulich-Bode, KM; Heller, A; Hoheisel, JD; Hotz-Wagenblatt, A; Keleg, S; Lathrop, M; Tost, J | 1 |
| Aranda, E; Arrivi, A; Bando, I; Benavides, M; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Gómez-España, A; González, E; Manzano, JL; Marcuello, E; Martínez de Prado, P; Massutí, B; Montagut, C; Reboredo, M; Rivera, F; Safont, MJ; Sastre, J | 1 |
| Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ | 1 |
| Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M | 1 |
| Belaygorod, L; Belt, BA; Brennan, DJ; Carpenter, D; Collins, L; DeNardo, DG; Gallagher, WM; Goedegebuure, P; Hewitt, S; Knolhoff, BL; Linehan, DC; Mitchem, JB; Piwnica-Worms, D; Sanford, DE; Udupi, GM; Wang-Gillam, A; Wegner, C; West, BL; Zhu, Y | 1 |
| Cai, RG; Ding, XY; Fan, Y; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
| Champeny, TL; Chang, JE; Hansen, RM; Kim, K; Meadows, S; Njiaju, UO; Powers, K; Stewart, JA; Tevaarwerk, AJ; Traynor, AM; Van Ummersen, L | 1 |
| Gibbs, P; Hack, SP; Kerr, A; Price, T; Stokes, L; Todd, C; Tran, G | 1 |
| Cai, S; Guan, Z; Lian, P; Liang, L; Liu, F; Wang, M; Xu, J; Xu, Y; Zhang, Z; Zhu, J | 1 |
| Jiang, Y; Li, Q; Liu, J; Wei, W; Yang, H | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N | 1 |
| Furuya, Y; Ishida, T; Masuda, N; Matsunami, N; Miyashita, M; Nagata, T; Nakayama, T; Noguchi, S; Nomura, M; Oba, K; Sakamoto, J; Taguchi, T; Wakita, K; Yamamoto, D; Yoshidome, K; Yoshino, H | 1 |
| Apolo, AB; Bajorin, DF; Balar, AV; Gallagher, DJ; Garcia-Grossman, IR; Iasonos, A; Milowsky, MI; Mironov, S; Ostrovnaya, I; Regazzi, AM; Trout, A | 1 |
| Vogelzang, NJ | 1 |
| Elghazaly, H; Rostom, Y; Tawfik, H | 1 |
| Kato, T; Okamura, R; Sata, R | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D | 1 |
| Ardizzoni, A; Bisagni, G; Boni, C; De Matteis, A; Gamucci, T; Gnoni, R; Gori, S; Moretti, G; Musolino, A; Nuzzo, F; Panebianco, M; Passalacqua, R | 1 |
| O'Shaughnessy, JA | 1 |
| Perez, EA; Qu, G | 1 |
| Colle, B; Debourdeau, P; Estival, JL; Pavic, M; Teixeira, L; Zammit, C | 1 |
| Bolognia, JL; Glusac, EJ; Willey, A | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Díaz-Rubio, E; González-Larriba, JL; Guillem, V; Paz-Ares, L | 1 |
| Brooks, DJ; Jones, RE; Orenberg, EK; Rodriguez, GI; Stoltz, ML | 1 |
| Blagden, S; Blesing, C; Corrie, P; D'Ath, S; Mayer, A; Price, P; Shaw, J; Warner, N | 1 |
| Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
| Breddy, J; Cameron, D; Chaturvedi, A; Hutcheon, A; Leonard, RC; Salazar, R; Twelves, C | 1 |
| Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B | 1 |
| Bruns, CJ; Ellis, LM; Harbison, MT; Hicklin, DJ; Jauch, KW; Portera, C; Radinsky, R; Shrader, M; Solorzano, CC | 1 |
| Kulke, MH | 1 |
| Fuxius, S; Mansouri, K; Mross, K; Unger, C | 1 |
| Baker, CH; Dinney, CP; Fidler, IJ; Kedar, D; Killion, JJ | 1 |
| Gambill, BD | 1 |
| Fishman, AD; Wadler, S | 1 |
| Besse, B; Spano, JP | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Misset, JL; O'Shaughnessy, J; Seidman, AD | 1 |
| Bouvet, M; Hoffman, RM; Moossa, AR; Nassirpour, R; Sun, FX; Tohgo, A; Yagi, S | 1 |
| Aglione, S; Bajetta, E; Bidoli, P; Cortinovis, D; De Candis, D; Formisano, B; Mariani, L; Stani, SC; Zaffaroni, N; Zilembo, N | 1 |
| Abbruzzese, JL; Bedford, R; Freeman, SM; Hecht, JR; Kirn, DH; Lahoti, S; Reid, TR; Soetikno, RM | 1 |
| Dühmke, E; Heinemann, V; Rau, HG; Stoffregen, C; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N | 1 |
| Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG | 1 |
| Accurso, V; Capaccetti, B; Cascinu, S; Catalano, V; Ferraù, F; Filippelli, G; Franciosi, V; Gasparini, G; Gattuso, D; Morabito, A; Palmeri, S; Scinto, F; Zagonel, V | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Alberts, SR; Cha, SS; Fitch, TR; Goldberg, RM; Krook, JE; Mailliard, JA; Moore, DF; Pitot, HC; Sargent, DJ; Townley, PM; Wiesenfeld, M | 1 |
| Seidman, AD | 2 |
| Fumoleau, P | 1 |
| Sledge, GW | 2 |
| O'shaughnessy, J | 3 |
| Fehn, K; Landau, L; Makower, D; Mani, S; Sparano, JA; Versola, M; Wadler, S; Wissel, P | 1 |
| Ardine, M; Bergnolo, P; Berruti, A; Bertetto, O; Coccorullo, Z; Comandone, A; Donadio, M; Fea, E; Mistrangelo, M; Ritorto, G | 1 |
| Ilersich, AL; Verma, S | 1 |
| Oettle, H | 1 |
| Johansson, R; Kataja, V; Pulkkanen, K | 1 |
| Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G | 1 |
| Bouvet, M; Hoffman, RM; Katz, MH; Moossa, AR; Spivack, D; Takimoto, S | 1 |
| Colwell, B; Dagenais, M; Dancey, J; Eisenberg, PD; Fields, A; Greenberg, B; Hagan, K; Hamm, J; Humphrey, R; Moore, MJ; Ottaway, J; Seymour, L; Tu, D; Zee, B | 1 |
| Arun, B; Booser, D; Esteva, FJ; Gibbs, A; Hortobagyi, GN; Murray, JL; Nealy, KM; Pusztai, L; Rivera, E; Smith, TL; Symmans, WF; Thompson, WJ; Valero, V; Whitehead, C; Zhen, JH | 1 |
| Blum, JL; Fumoleau, P; Reichardt, P | 1 |
| Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F | 1 |
| O'Neil, BH | 1 |
| Bartsch, R; Hussian, D; Kramer, G; Lintner, C; Locker, GJ; Mader, R; Marberger, M; Pluschnig, U; Rauchenwald, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S | 1 |
| Begbie, S; Borner, M; Burns, WI; Burris, HA; Cassidy, J; Garcia-Alfonso, P; Jodrell, D; Koralewski, P; Levine, EL; Maroun, J; Marschner, N; McKendrick, J; Scheithauer, W; Tujakowski, J; Twelves, C; Van Hazel, G; Wong, A; Zaluski, J | 1 |
| Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Gerasimidis, G; Kandilis, K; Karamouzis, MV; Karydas, I; Rigatos, G; Stavrakakis, J; Stavrinides, H; Tryfonopoulos, D | 1 |
| Lewis, NL; Meropol, NJ | 1 |
| Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G | 1 |
| Ali, SA; Fareed, A; Mallick, JA; Siddiqui, N | 1 |
| Cats, A | 1 |
| Modi, S; Seidman, AD | 1 |
| Perez, EA | 1 |
| DeMichele, A; Domchek, S; Fox, K; Stein, S | 1 |
| Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N | 1 |
| Seidman, A | 1 |
| Balbiani, L; Brosio, C; Caccia, G; Delfino, C; Flores Morales, D; Mickiewicz, E; Riva Gonzáles, L; Rodger, J; Zori Comba, A | 1 |
| Murad, AM | 1 |
| Zielinski, CC | 2 |
| Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K | 1 |
| Audhuy, B; Clippe, C; Culine, S; Curé, H; Dièras, V; Fumoleau, P; Largillier, R; Lesimple, T; Montestruc, F; Morère, JF; Mouri, Z; Namer, M; Orfeuvre, H; Serin, D; Vuillemin, E | 1 |
| Bukowski, RM; Cunningham, D; Dufour, P; Graeven, U; Harper, P; Hoff, PM; Lokich, J; Madajewicz, S; Maroun, JA; Marshall, JL; Mitchell, EP; Perez-Manga, G; Rougier, P; Schilsky, RL; Schmiegel, W; Schoelmerich, J; Sobrero, A; Van Cutsem, E | 1 |
| Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M | 1 |
| Ashley, SW; Duxbury, MS; Ito, H; Whang, EE; Zinner, MJ | 1 |
| Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T | 1 |
| Bremnes, Y; Mjaaland, I; Ostenstad, B; Risberg, T; Sommer, HH; Wist, EA | 1 |
| Stadler, WM | 2 |
| Abbruzzese, JL; Carter, S; Hoff, PM; Lassere, Y; Pazdur, R; Polito, D; Samid, D | 1 |
| Calvo, I; Casado, V; Daz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; Sánchez-Rovira, P | 1 |
| Kimmel, G; Marsland, T; O'Shaughnessy, JA; Pippen, JE; Ratnam, S; Vukelja, S | 1 |
| Hamilton, M; Karvellas, CJ; Mackey, JR; Sawyer, M | 1 |
| Buksmaui, S; Hausmaninger, H; Heinrich, B; Höffken, K; Krejcy, K; Miller, MA; Morack, G; Possinger, K; Wallwiener, D | 1 |
| Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Ahn, JH; Ahn, SH; Kang, YK; Kim, SB; Kim, SM; Kim, TW; Kim, WK; Lee, JS; Park, JM | 1 |
| Abraham, NG; Gorschlüter, M; Märten, A; Nagaraj, S; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J; Ziske, C | 1 |
| Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ | 1 |
| Anagnostopoulos, A; Aravantinos, G; Athanasios Dimopoulos, M; Bafaloukos, D; Bamias, A; Deliveliotis, C; Efstathiou, E; Kalofonos, C; Linardou, H | 1 |
| Desjardins, P; Hirsh, V; Laberge, F; Langleben, A; Latreille, J; Samson, B; Whittom, R | 1 |
| Dutcher, JP; Garino, A; Larkin, M; Milowsky, MI; Nanus, DM | 1 |
| Leonard, R; Miles, D; Reichardt, P; Twelves, C | 1 |
| A'hern, R; Eisen, T; Gore, M; Hackett, S; James, M; Moss, C; Pyle, L; Waters, JS | 1 |
| Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS | 1 |
| Barauskas, G; Brasiūnas, V; Brasiūniene, B; Juozaityte, E | 1 |
| Aebi, S; Ballabeni, P; Castiglione-Gertsch, M; Goldhirsch, A; Hess, D; Pagani, O; Rauch, D; Rufener, B; Thürlimann, B | 1 |
| Saeki, T; Takashima, S | 1 |
| Bobek, V; Boubelik, M; Hoffman, RM; Jiang, P; Kolostova, K; Pinterova, D; Plachy, J; Yang, M | 1 |
| Aboulafia, DM; Jacobs, AD; Otero, H; Picozzi, VJ | 1 |
| Borquez, D; Harstrick, A; Kaufmann, M; Loibl, S; Oberhoff, C; Schleucher, R; Seeber, S; Vanhoefer, U; von Minckwitz, G; Welt, A | 1 |
| Hribaschek, A; Lippert, H; Lueck, A; Meyer, F; Ridwelski, K | 1 |
| Furuse, J; Ishii, H; Nagase, M; Yoshino, M | 1 |
| Alberts, SR; Erlichman, C; Fitch, TR; Foster, NR; Moore, DF; Nair, S; Rowland, KM; Schroeder, M; Steen, PD; Tschetter, LK | 1 |
| Maeyama, R; Manabe, T; Matsuda, T; Mizumoto, K; Okino, H; Tanaka, M | 1 |
| Cardaci, V; Cesario, A; Galetta, D; Granone, P; Margaritora, S; Onorati, D; Piraino, A; Porziella, V; Vita, L | 1 |
| Huang, WG; Jia, L; Yuan, SZ; Zhang, MH | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Ottaviani, D; Polimeni, MA | 1 |
| Berger, MR; Eyol, E; Rodenbach, M; Seelig, MH | 1 |
| Casaretti, R; Comella, P; Farris, A; Gambardella, A; Leo, S; Lorusso, V; Maiorino, L; Massidda, B; Natale, D; Tafuto, S | 1 |
| Chap, LI; Cobleigh, MA; Dickler, M; Fehrenbacher, L; Holmes, FA; Langmuir, V; Marcom, PK; Miller, KD; Overmoyer, BA; Reimann, JD; Rugo, HS; Sing, AP | 1 |
| Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H | 1 |
| Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ | 1 |
| Bertheault-Cvitkovic, F; Bugat, R; Canal, P; Chatelut, E; Cornen, X; Delord, JP; Dieras, V; Guimbaud, R; Lochon, I; Lokiec, F; Mery-Mignard, D; Mouri, Z; Pierga, JY; Turpin, FL | 1 |
| Androulakis, N; Aravantinos, G; Georgoulis, V; Mallas, K; Polyzos, A; Stathopoulos, GP; Syrigos, K; Vamvakas, L; Ziras, N | 1 |
| Bafaloukos, D; Bamias, A; Economopoulos, T; Efstathiou, E; Gogas, H; Kalofonos, H; Kastritis, E; Kosmidis, P; Onyenadum, A; Papacostas, P; Samantas, E; Samelis, G; Skarlos, D; Xiros, N | 1 |
| Burch, PA; Cannon, MW; Hillman, DW; Ingle, JN; Krook, JE; Mailliard, JA; Perez, EA; Rowland, KM; Veeder, MH | 1 |
| Advani, SH; Doval, DC; Ermisch, S; Feher, O; Jassem, J; Khoo, KS; Miller, MA; Morack, G; Roychowdhury, D; Vodvarka, P; von Minckwitz, G | 1 |
| Chung, HC; Jeung, HC; Kim, GE; Kim, YT; Moon, YH; Rha, SY; Roh, JK; Sohn, JH; Suh, CO; Yang, WI | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Cannone, M; Casaretti, R; Comella, P; Farris, A; Gambardella, A; Leo, S; Lorusso, V; Maiorino, L; Massidda, B; Natale, D; Tafuto, S | 1 |
| Kahlert, S; Konecny, G; Rueckert, S; Ruehl, I; Untch, M | 1 |
| Adrian, TE; Bell, RH; Ding, XZ; Hennig, R; Iwamura, T; Jovanovic, BD; Rao, SM; Segersvard, R; Talamonti, MS; Ventura, J; Ward, E | 1 |
| Alexandrescu, DT; Dutcher, JP; Wiernik, PH | 1 |
| Arning, M; Dogliotti, L; Moore, MJ; Oliver, T; Ricci, S; Roberts, JT; Sengelov, L; von der Maase, H; Zimmermann, A | 1 |
| Dieing, A; Flath, B; Heilmann, V; Jehn, C; Lehenbauer-Dehm, S; Possinger, K; Schmid, P; Schulz, CO; Sezer, O | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Arning, M; Fuchs, M; John, W; Kindler, HL; Oettle, H; Peeters, M; Ramanathan, RK; Richards, D; van Laethem, JL; Von Hoff, D; Zimmermann, A | 1 |
| Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP | 1 |
| Abbas, J; Al-Kutoubi, A; Bikhazi, AB; Chehal, AA; Habbal, MZ; Khalifeh, MJ; Malaeb, LA; Mourad, FH; Shamseddine, AI | 1 |
| Clemons, M; Dranitsaris, G; Joy, AA; MacKey, JR; Trudeau, M; Verma, S | 1 |
| Alexandre, J; Amsellem-Ouazana, D; Beuzeboc, P; Debré, B; Flam, T; Goldwasser, F; Guillevin, L; Mir, O; Ropert, S; Zerbib, M | 1 |
| Fioravanti, S; Grem, JL; Harold, N; Leonard, GD; Quinn, MG; Schuler, B; Thomas, RR; Wright, MA | 1 |
| Bechrakis, NE; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
| Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Saraydaroglu, O; Tasdelen, I; Tolunay, S; Topal, U | 1 |
| Albritton, K; Anderson, PM; Dubansky, SA; Erlandson, L; Rodriguez, V; Trotz, B; Wiseman, GA | 1 |
| Coleman, RE; El-Helw, L | 1 |
| Baddi, L; Beck, AC; Blumenthal, DT; Chua-Adajar, R; Futterer, S; Gradishar, W; Raizer, JJ; Semenov, I; Simuni, T; Tellez, C; Videnovic, A | 1 |
| Barge, A; Bruns, CJ; Friedrich, M; Jauch, KW; Kleespies, A; Köhl, G; Ryan, AJ | 1 |
| An, CH; Bang, SM; Cho, EK; Jeong, SH; Kyung, SY; Lee, JH; Lee, SP; Lim, YH; Park, JW; Park, SH; Shin, DB | 1 |
| Leow, CH; Liam, CK | 1 |
| Moreno-Aspitia, A; Perez, EA | 1 |
| Cameron, D; Dunlop, D; Eatock, M; McClory, B; Millar, J; Morrison, A; Philips, H; Price, A; Scullin, P; Wall, L | 1 |
| Lokiec, F; Rezaí, K; Urien, S | 1 |
| Adamoli, L; Blanchot, G; Catania, C; Goldhirsch, A; Imadalou, K; Longerey, B; Munzone, E; Nolè, F; Sanna, G | 1 |
| Adjei, AA; Fitch, TR; Hillman, DW; Ingle, JN; Kugler, JW; Ma, CX; Niedringhaus, RD; Perez, EA; Rowland, KM; Steen, P | 1 |
| Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Adamo, B; Adamo, V; Alafaci, E; Garipoli, C; Magno, C; Maisano, C; Rossello, R; Scandurra, G; Scimone, A; Spitaleri, G | 1 |
| Alabiso, O; Ardine, M; Beano, A; Berruti, A; Bertetto, O; Bonardi, S; Bottini, A; Bretti, S; Castiglione, F; Donadio, M; Generali, D; Mistrangelo, M; Polimeni, MA | 1 |
| Furuse, J; Ikeda, M; Ishiguro, Y; Ishii, H; Matsubara, J; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H | 1 |
| Morse, MA | 1 |
| Airoldi, M; Cattel, L; Milla, P; Passera, R; Pedani, F; Zanon, C | 1 |
| Barnett, CC; Beck, AW; Brekken, RA; Conner, CR; Fleming, JB; Holloway, SE; Luster, TA; Miller, AF; Thorpe, PE | 1 |
| Barnadas, A | 1 |
| Fumoleau, P; Levy, C | 1 |
| Colomer, R | 1 |
| Beha, M; Brudler, O; Heinemann, V; Kahlert, S; Müller, S; Stauch, B; Stemmler, HJ | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martín-Richard, M; Mayordomo, JI; Pelegrí, A; Vásquez, S; Virizuela, J | 1 |
| Guo, Y; Hong, XN; Li, J; Tang, WY; Wang, JL | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B | 1 |
| Goyle, S; Maraveyas, A | 1 |
| Alliot, C | 1 |
| Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
| Aprile, G; Balzano, G; Bonetto, E; Brandes, AA; Cordio, S; Dell'Oro, S; Di Carlo, V; Fugazza, C; Luppi, G; Milandri, C; Nicoletti, R; Pasetto, L; Passoni, P; Piemonti, L; Reni, M; Zerbi, A | 1 |
| Hennemann, B | 1 |
| Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R | 1 |
| Asmar, L; Ilegbodu, D; Khandelwal, P; O'Shaughnessy, JA; Pluenneke, R; Sternberg, J | 1 |
| Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Yoon, SJ; Yoon, SM | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX | 1 |
| Aguirre, G; Alexander, F; Avila, E; Calderillo, G; Fuentes, H; Gallardo, D; Oñate-Ocaña, LF; Otero, J; Perez, L; Ramirez, M | 1 |
| Thigpen, T | 1 |
| Ishihara, T; Kato, H; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
| Caprio, G; Di Seri, M; Frati, L; Romiti, A; Spinelli, GP; Terzoli, E; Tomao, F; Tomao, S | 1 |
| Calabrò, F; Mancuso, A; Sternberg, CN | 1 |
| Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P | 1 |
| Laurie, SA; Licitra, L | 1 |
| Choi, CW; Kim, AR; Kim, BS; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Seo, JH; Shin, SW | 1 |
| Allen, J; Hauger, M; Kendra, K; Merriman, N; Moore, T; Mrozek, E; Nadella, P; Ramaswamy, B; Rhoades, CA; Shapiro, CL; Villalona-Calero, M; Watson, H; Young, D | 1 |
| Arning, M; Conte, PF; Dogliotti, L; Moore, MJ; Oliver, T; Roberts, JT; Sengeløv, L; von der Maase, H; Zimmermann, A | 1 |
| Ferrazzi, E; Stievano, L | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Bearz, A; Binato, S; Cartei, G; Ceravolo, R; Cingarlini, S; Colombrino, E; Fantoni, U; Iop, A; Palamidese, A; Sacco, C; Scalone, S | 1 |
| Cauchi, C; Gridelli, C; Rinaldi, M | 1 |
| Amici, S; Bonginelli, P; Bonsignori, M; Carillio, G; De Sio, L; Fanelli, M; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Massaccesi, C; Morabito, A; Torino, F | 1 |
| Endo, I; Fujii, Y; Ichikawa, Y; Kubota, T; Miura, Y; Shimada, H; Tanaka, K; Togo, S; Ueda, M | 1 |
| Bustam, A; Khoo, KS; Lehnert, M; Manzoor Zaidi, SH; Nair, R; Ngelangel, CA; Reece, WH; Song, S; Srimuninnimit, V | 1 |
| Chen, G; Geertsen, PF; Gough, J; Gravis, G; Joensuu, H; Kania, M; Lehmann, J; von der Maase, H | 1 |
| Akerley, W; Kennedy, T; Mega, T; Ready, N; Safran, H; Zaner, K | 1 |
| Chao, TC; Chen, PM; Hsiao, LT; Lin, PC; Wang, WS; Yang, MH; Yen, CC | 1 |
| Androulakis, N; Aravantinos, G; Boukovinas, J; Fountzilas, G; Georgoulias, V; Kotsakis, A; Papakotoulas, P; Polyzos, A; Potamianou, A; Samonis, G; Stathopoulos, GP; Syrigos, K; Varthalitis, J; Ziras, N | 1 |
| Barrier, R; Davila, E; Ernstoff, MS; Halabi, S; Picus, J; Rini, B; Small, EJ; Stadler, WM | 1 |
| Gilliam, LK; Kohn, AD; Lalani, T; Livingston, RB; Patel, A; Pickett, CA; Swanson, PE; Vasko, V | 1 |
| Caricato, M; Coppola, R; Di Seri, M; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S | 1 |
| Tu, LF; Wang, LH; Wang, XF; Zhou, JY | 1 |
| Helke, C; Hoschke, B; May, M | 1 |
| Airoldi, M; Cattel, L; Delprino, L; Micari, C; Passera, R; Pedani, F | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Delaunay, M; Jouary, T; Kaiafa, A; Lepreux, S; Lipinski, P; Taïeb, A; Vergier, B | 1 |
| Bozec, L; Campone, M; Diéras, V; Espié, M; Fumoleau, P; Kayitalire, L; Petit, T; Pouillart, P; Pujade-Lauraine, E; Serin, D; Viens, P | 1 |
| Amarantidis, K; Christophillakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kalbakis, K; Malamos, N; Mavroudis, D; Mavrousis, D; Potamianou, A; Tselepatiotis, E; Vamvakas, L | 1 |
| Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L | 1 |
| Abbruzzese, JL; Baschnagel, A; Crane, CH; Das, P; Delclos, ME; Evans, DB; Janjan, NA; Krishnan, S; Varadhachary, GR; Vauthey, JN; Wolff, RA | 1 |
| Albanell, J; Carles, J; Doménech, M; Fabregat, X; Font, A; Gallén, M; Mesía, C; Nogué, M; Suárez, C; Suárez, M; Tusquets, I | 1 |
| Fok, JY; Kumar, R; Manavathi, B; Mann, AP; Mehta, K; Verma, A; Wang, H | 1 |
| Fasolo, A; Gianni, L; Marchiano, A; Mariani, G; Moliterni, A; Petrelli, F; Valagussa, P; Zambetti, M | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS | 1 |
| Leoni, V; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Ajiki, T; Fujimori, T; Fujita, T; Hirata, K; Hori, H; Horiuchi, H; Kamigaki, T; Kuroda, Y; Mita, Y; Okazaki, T | 1 |
| Bokemeyer, C; Grünwald, V; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Rick, O | 1 |
| Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T | 1 |
| Evrensel, T; Goker, E; Kurt, E; Manavoglu, O; Ozdemir, N; Sezgin, C | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Kim, WK; Lee, JL; Lee, JS; Lee, SS; Ryu, MH | 1 |
| Heinemann, V | 2 |
| Adrover, E; Balil, A; Calvo, L; Carrasco, E; Casado, A; Escudero, MJ; García-Mata, J; García-Saenz, JA; Guillem, V; Jara, C; Mahillo, E; Martín, M; Mel, JR; Morales-Vasquez, F; Muñoz, M; Ribelles, N; Rodríguez, CA; Ruiz, A; Salas, F; Soto, C | 1 |
| Alvarez, H; Beaty, R; Bedja, D; Dhara, S; Feldmann, G; Fendrich, V; Gabrielson, KL; Iacobuzio-Donahue, C; Jimeno, A; Karikari, C; Maitra, A; Matsui, W; Mullendore, M | 1 |
| Cheng, AL; Hsu, CH; Huang, CY; Huang, KH; Keng, HY; Lin, CC; Pu, YS; Tsai, YC | 1 |
| Ahn, MJ; Kim, HK; Kim, JS; Kim, TY; Lee, J; Lee, MA; Lee, NS; Lim, HY; Park, BJ | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Bremer, M; Karstens, JH; Schwarte, S; Wagner, K | 1 |
| Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M | 1 |
| Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G | 1 |
| Creaven, P; Levine, E; O'connor, T; Rustum, Y | 1 |
| Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S | 1 |
| Doorn, L; Eskens, FA; van der Gaast, A; van Gameren, EC; van Meerten, E | 1 |
| Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J | 1 |
| Clegg, AJ; Jones, J; Loveman, E; Takeda, AL; Tan, SC | 1 |
| Tripathy, D | 2 |
| Díaz-Rubio, E; García-Saénz, JA; Martín, M | 1 |
| Choi, IK; Chun, HJ; Jeen, YT; Kim, JS; Kim, YH; Mok, YJ; Oh, SC; Park, SS; Seo, JH; Shin, SW; Sung, HJ; Sur, HY | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T | 1 |
| Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J | 1 |
| Charoentum, C; Chewaskulyong, B; Munprakan, S; Thongprasert, S | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 1 |
| Barbanti, G; de Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A | 1 |
| Brun, V; Gravis, G; Labidi, SI; Tarpin, C; Viens, P | 1 |
| Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS | 1 |
| Baker, LH; Benjamin, RS; Fanucchi, M; Harmon, DC; Hensley, ML; Maki, RG; Okuno, SH; Patel, SR; Priebat, DA; Reinke, D; Samuels, B; Schuetze, SM; Thall, PF; Wathen, JK | 1 |
| Bosserman, L; Cai, C; Hortobagyi, GN; Lerzo, G; Mullaney, B; Peck, R; Perez, EA; Pivot, X; Thomas, E; Vahdat, L; Viens, P | 1 |
| Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY | 1 |
| Fenoglio-Preiser, C; Hingorani, SR; Lowy, AM; Revelo-Penafiel, MP; Thomas, RM; Toney, K; Tuveson, DA; Waltz, SE | 1 |
| Irisawa, A; Kanazawa, M; Ogata, T; Ohira, H; Ohto, H; Sato, Y; Takagi, T; Takenoshita, S | 1 |
| Iguchi, C; Kan, N; Kodama, H; Nio, Y; Yoshikawa, K | 1 |
| Bianco, A; Campbell, S; Caputo, F; D'Agostino, D; Gilli, M; Marsico, SA; Mazzarella, G; Piantedosi, FV; Pontillo, A | 1 |
| Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L | 1 |
| Brand, RE; Carneiro, BA; Fine, E; Khandekar, JD; Knop, RH; Locker, GY; Uhlig, W | 1 |
| Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO | 1 |
| Hagihara, A; Ikeda, M; Morizane, C; Ogura, T; Okusaka, T; Tanaka, T; Ueno, H | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Biville, F; Chauffert, B; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Garnier, J; Isambert, N; Mayer, F; Zanetta, S | 1 |
| Aoki, K; Ikeda, T; Kikugawa, T; Ochi, T; Ozawa, A; Shimamoto, K; Tanji, N; Toshino, A; Yamaguchi, A; Yanagihara, Y; Yokoyama, M | 1 |
| Amato, RJ; Khan, M | 1 |
| Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C | 1 |
| Mayer, RJ | 1 |
| Cho, EY; Hong, YS; Im, YH; Kang, WK; Kim, HS; Kim, K; Kim, MJ; Lee, HR; Lee, J; Park, K; Shim, YM | 1 |
| Hatake, K; Ito, Y; Iwase, T; Osako, T; Takahashi, S; Tokudome, N | 1 |
| Baldazzi, V; Carini, M; Crisci, A; Giordano, C; Grifoni, R; Lapini, A; Neri, B; Pantaleo, P; Raugei, A; Vannini, L | 1 |
| Ammann, M; Duquesne, A; Fürstenberger, G; Schmid, P; Senn, HJ | 1 |
| Andrieu, JM; Banu, A; Banu, E; Chatellier, G; Fodor, A; Landi, B; Oudard, S; Rougier, P | 1 |
| Guan, ZZ; Huang, PY; Peng, PJ; Xu, F; Zhang, L; Zhang, Y | 1 |
| Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T | 1 |
| Gel-Moreno, B; Hernández-Borlan, R; Ibeas-Rollan, R; Martínez-Ródenas, F; Monzó-Planella, M; Moreno-Solórzano, I; Moreno-Solórzano, J; Navarro-Vigo, M; Ortigosa-Rodríguez, S; Pou-Sanchis, E | 1 |
| Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J | 1 |
| Ahn, E; Flores, A; Lopes, G; Quesada, J; Ribeiro, A; Rocha-Lima, CM | 1 |
| Campone, M; Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Gomez, HL; Jassem, J; Klimovsky, JV; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Thomas, ES; Vahdat, LT; Xu, B | 1 |
| Saif, MW; Tejani, MA | 1 |
| Gemma, A; Kudoh, S; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Okano, T; Shibuya, M; Takemura, A; Yoshimura, A | 1 |
| Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C | 1 |
| Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F; Semrau, S | 1 |
| Battistelli, S; Civitelli, S; Fiaschi, AI; Francini, E; Francini, G; Lorenzi, M; Marsili, S; Pascucci, A; Petrioli, R; Roviello, F; Tanzini, G | 1 |
| Geboes, K; Van Cutsem, E | 1 |
| Jiang, WQ; Liu, DG; Teng, XY; Zhou, NN | 1 |
| Heinemann, V; Wilkowski, R; Wolf, M | 1 |
| Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY | 1 |
| Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Chang, HM; Cho, JY; Do, YR; Hong, DS; Kim, SY; Kim, YH; Lee, KE; Lee, KH; Ryu, MH; Song, HS | 1 |
| Chen, Y; Deng, YM; He, YJ; Hu, GQ; Jiang, WQ; Li, YH; Lin, Q; Wang, FH; Xiang, XJ; Xu, DM | 1 |
| de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M | 1 |
| Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH | 1 |
| Atienza, D; Awasthi, S; Berry, W; Delaune, R; Deutsch, M; Dien, PY; Gregory, TF; Hood, K; Hutson, TE; Ilegbodu, D; Kolodziej, MJ; Mull, S; Muscato, JJ; Nicol, S; Raju, RN; Ruxer, RL; Vukelja, S | 1 |
| Amos, KD; Arumugam, T; Evans, DB; Hwang, RF; Ji, B; Logsdon, CD; Moore, T; Ramachandran, V; Rivera, A | 1 |
| Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T | 1 |
| Altorjai, G; Bartsch, R; Dubsky, P; Gampenrieder, SP; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T | 1 |
| Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S | 1 |
| Fujino, Y; Kuroda, Y; Sakai, T | 1 |
| Bergsland, EK; Dito, E; Hwang, J; Ko, AH; Schillinger, B; Scott, J; Tempero, MA; Venook, AP; Wong, D; Xu, Z | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Alberts, SR; Carlson, SK; Foster, NR; Galanis, E; Grothey, A; Jatoi, A; Lowe, V; McWilliams, RR; Quevedo, F; Rubin, J | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H | 1 |
| Hilbig, A; Oettle, H | 1 |
| Nagai, T; Ohgaki, K; Sugie, T | 1 |
| Vahdat, LT | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, L; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS | 1 |
| Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, LB; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS | 1 |
| Allegra, C; Bertino, JR; Cassidy, J; Clarke, SJ; Cunningham, D; Douillard, JY; Gilberg, F; Gustavsson, BG; Haller, DG; Hoff, PM; Milano, G; O'Connell, M; Rothenberg, ML; Rustum, Y; Saltz, LB; Schmoll, HJ; Sirzén, F; Tabernero, J; Twelves, C; Van Cutsem, E | 1 |
| Thomas, ES | 1 |
| Cartwright, TH; Chu, E | 1 |
| Cassidy, J; Schmoll, HJ; Van Cutsem, E | 1 |
| Michelin, OC; Paiva, CE | 1 |
| Bertoldi, I; Correale, P; Fioravanti, A; Francini, G; Miracco, C; Montagnani, F | 1 |
| Amato, RJ; Mohammad, T | 1 |
| Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Adamo, B; Adamo, V; Condemi, G; Di Lullo, L; Ferrandina, G; Ferraro, G; Lorusso, D; Lorusso, V; Paglia, A; Pisconti, S; Priolo, D; Rossello, R; Scambia, G | 1 |
| Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP | 1 |
| Beykirch, M; Carmichael, J; Harris, AL; Kerr, H; Phillip, P; Possinger, K; Walling, J | 1 |
| Calabresi, F; Ceribelli, A; Crecco, M; Pollera, CF | 1 |
| Bitonti, AJ; Bush, TL; Cashman, EA; Cross-Doersen, DE; Dumont, JA; Kaplan, DA; Matthews, DP; McCarthy, JR; Wright, PS | 1 |
| Kennedy, MJ | 1 |
| Dorr, FA; Kuzel, TM; Levine, E; Raghavan, D; Roth, B; Stadler, WM; Vogelzang, NJ | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, P; ten Bokkel Huinink, W; van Walree, N; von Pawel, J; Wagenius, G | 1 |
| Abratt, RP; Bezwoda, WR; Goedhals, L; Hacking, DJ | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, RA; ten Bokkel-Huinink, W; van Pawel, J; van Walree, N; Wagenius, G | 1 |
| Coucke, PA; Guillou, L; Li, YX; Mirimanoff, RO; Sun, LQ | 1 |
| John, WJ; Mohiuddin, M; Regine, WF | 1 |
| Athanassiades, A; Bacoyiannis, C; Briassoulis, E; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Fukase, Y; Ishikawa, T; Ishitsuka, H; Sekiguchi, F; Yamamoto, T | 1 |
| Blaszkowsky, L | 1 |
| Akrivakis, C; Flath, B; Grunewald, R; Lüftner, D; Mergenthaler, HG; Possinger, K | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E | 1 |
| Bareck, E; Depisch, D; Funovics, J; Hejna, M; Kornek, GV; Kovats, E; Lang, F; Miholic, J; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Akrivakis, K; Flath, B; Grosse, Y; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O | 1 |
| Adjei, AA; Erlichman, C | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Armand, JP; Baudin, E; Boige, V; Chaouche, M; Chouaki, N; Delord, JP; Ducreux, M; Escudier, B; Faivre, S; Kayitalire, L; Le Chevalier, T; Pautier, P; Raymond, E; Rixe, O; Rodier, JM; Ruffie, P | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; De Paz, L; Fernández, Y; Guillem, V; Llombart, A; Lluch, A; Ojeda, B | 1 |
| Aisner, J; Carducci, M; Kaufman, D; Kuzel, T; Levine, EG; Murphy, B; Nicol, S; Oh, W; Raghavan, D; Stadler, W | 1 |
| Abbruzzese, JL; Bruns, CJ; Davis, DW; Evans, DB; Harbison, MT; Hicklin, DJ; McConkey, DJ; Portera, CA; Radinsky, R; Tsan, R | 1 |
| von der Maase, H | 2 |
| Atzpodien, J; Buer, J; Franzke, A; Hoffmann, R; Kirchner, H; Oevermann, K; Patzelt, T; Schrader, A | 1 |
| Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S | 1 |
| Bafaloukos, D; Dimopoulos, MA; Fountzilas, G; Kalofonos, C; Kosmidis, P; Nicolaides, C; Pavlidis, N; Razi, E; Samantas, E | 1 |
| Albers, P; Bodrogi, I; Cleall, SP; Conte, PF; Dogliotti, L; Hansen, SW; Kerbrat, P; Knuth, A; Lippert, CM; Moore, MJ; Oliver, T; Roberts, JT; Roychowdhury, DF; Sanchez Rovira, P; Tomlin, I; Visseren-Grul, CM; von der Maase, H; Wersall, P | 1 |
| Einhorn, LH; Kindler, HL; Kraut, M; Masters, G; Mitchell, E; Nicol, S; Raghavan, D; Sandler, AB | 1 |
| Brodowicz, T; Függer, R; Jakesz, R; Köstler, WJ; Steger, GG; Teleky, B; Tomek, S; Vaclavik, I; Wolfram, RM; Zielinski, CC | 1 |
| Edelman, MJ | 1 |
| Azinovic, I; Brugarolas, A; Calvo, E; Cortes, J; de Irala, J; Fernandez-Hildago, O; Garzon, C; Martinez-Aguillo, M; Martinez-Monge, R; Ramon Y Cajal, T; Rodriguez, J | 1 |
| Arning, M; Clemens, M; Fink, U; Heinemann, V; Illiger, HJ; König, H; Mergenthaler, HG; Possinger, K; Schalhorn, A; Wilke, H | 1 |
| Alberola, V; Artal, A; Azagra, P; Camps, C; Carrato, A; Felip, E; González-Larriba, JL; Isla, D; Martin, C; Massutí, B; Rosell, R; Sánchez, JJ | 1 |
| Cohen, MH; Rothmann, M | 1 |
| Fan, J; Tang, Z; Zhou, J | 1 |
| Hortobagyi, GN | 2 |
| Georgoulias, VA | 1 |
| Nagourney, RA | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini'Neto, AO | 1 |
| Adjei, AA | 1 |
| Ansari, R; Gize, G; Miller, KD; Monaco, F; Nattam, S; Pennington, K; Sisk, J; Sledge, GW | 1 |
| Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B | 1 |
| Carrasco, E; Dueñas, R; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A | 1 |
| Bontenbal, M; de Heus, G; de Wit, R; Seynaeve, C; Smorenburg, CH; van Zuylen, C; Verweij, J | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Cuvier, C; Diéras, V; Espié, M; Ferrero, JM; Fumoleau, P; Kalla, S; Kayitalire, L; Llombart-Cussac, A; Namer, M; Perrocheau, G; Ponzio, A; Pouillart, P; Spielmann, M | 1 |
| Baranov, E; Bouvet, M; Hoffma, RM; Jiang, P; Lee, NC; Moossa, AR; Nardin, S; Rashidi, B; Wang, X; Yang, M | 1 |
| Baker, CH; Buchdunger, E; Cohen, P; Fidler, IJ; Killion, JJ; Solorzano, CC; Traxler, P; Tsan, R | 1 |
| Sternberg, CN | 1 |
| Albiol, S; Bellmunt, J | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R | 1 |
| Rixe, O | 1 |
| Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B | 1 |
| Leyland-Jones, B | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Araneo, M; Barzdins, A; Bruckner, HW; DeGregorio, P; Frager, D; Grossbard, ML; Homel, P; Kozuch, P; Marino, J; Robin, A | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N | 1 |
| Goa, KL; McGavin, JK | 1 |
| Athanasiadis, I; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdarides, D | 1 |
| Cartwright, TH; Chen, YM; Cohn, A; Cox, JV; Schulz, JJ; Szatrowski, TP; Varkey, JA | 1 |
| Baker, CH; Bruns, CJ; Ellis, LM; Fidler, IJ; Killion, JJ; Solorzano, CC; Wood, J | 1 |
| Ambinder, R; Blackstein, M; Cowan, J; Iglesias, J; Melemed, A; Vogel, CL | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P | 1 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
| Geoffroy, FJ; George, CM; Kollipara, P; Rini, BI; Stadler, WM; Vogelzang, NJ | 1 |
| Fong, KW; Foo, KF; Koh, L; Leong, SS; Lian, LG; Machin, D; Tai, BC; Tan, EH; Tan, T; Wee, JT | 1 |
| Albers, P; Blatter, J; Fallahi, M; Haeutle, D; Härtlein, M; Müller, SC; Perabo, FG; Siener, R; Steiner, G | 1 |
| Hussain, M; Smith, DC; Vaishampayan, U | 1 |
| Hargreaves, D; Ng, T; Nguyen-Van-Tam, J; Twelves, C | 1 |
| Morere, JF | 1 |
| Baker, CH; Fidler, IJ; Solorzano, CC | 1 |
| Awada, A; Batter, V; Beex, L; Biganzoli, L; Cufer, T; Hamilton, A; Lohrisch, C; Nooij, M; Piccart, M | 1 |
| Foo, KF; Machin, D; Tai, BC; Tan, EH; Tan, SB | 1 |
| Duan, Y; Guan, Z; Liu, X; Song, S; Wu, S; Yang, L; Yu, J | 1 |
| Ackland, S; Alba Conejo, E; Burger, HU; Eisenberg, P; Laws, S; Melnychuk, D; Moiseyenko, V; O'Reilly, SM; Osterwalder, B; Pienkowski, T; Talbot, DC; Van Belle, S | 1 |
| Heinemann, V; Schalhorn, A; Stemmler, J | 1 |
| Hwang, JJ; Marshall, JL | 1 |
| Kimmel, G; Marsland, T; O'Shaughnessy, J; Pippen, J; Ratnam, S; Vukelja, SJ | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Ryan, DP; Willett, CG | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Croockewit, AJ; de Boer, JE; Koopmans, PP; van Loenhout, JW | 1 |
| Greig, R; Kline, T; Mallon, F; Poste, G; Trainer, DL | 1 |
146 review(s) available for deoxycytidine and Neoplasm Metastasis
| Article | Year |
|---|---|
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Eligibility Determination; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Second-line treatment for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2017 |
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Metastasis; Pancreatic Ducts; Pancreatic Neoplasms; Signal Transduction | 2017 |
[Metastases of Urothelial Carcinoma with Trophoblastic Differentiation that Responded to Combination Chemotherapy with Gemcitabine and Oxaliplatin : A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Neoplasm Metastasis; Oxaliplatin; Urinary Bladder Neoplasms | 2018 |
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Diabetes Mellitus; Diet; Drug Resistance, Neoplasm; Early Detection of Cancer; Fluorouracil; Gemcitabine; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Radiosurgery; Risk Factors; Spain | 2019 |
Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Asia, Western; Breast Neoplasms; China; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2014 |
Treatment of metastatic pancreatic adenocarcinoma: a review.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2014 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Colitis; Contraindications; Deoxycytidine; Diagnosis, Differential; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Ileitis; Mutation; Neoplasm Metastasis; Triple Negative Breast Neoplasms | 2014 |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2014 |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Publication Bias | 2015 |
Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptors, Vascular Endothelial Growth Factor | 2015 |
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Risk Factors; Treatment Outcome | 2015 |
The safety and efficacy of gemcitabine for the treatment of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Urinary Bladder Neoplasms | 2016 |
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Odds Ratio; Organoplatinum Compounds; Oxaloacetates; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Safety of palliative chemotherapy in advanced pancreatic cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms | 2017 |
Metastatic pancreatic cancer 2008: is the glass less empty?
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Disease-Free Survival; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2008 |
Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
Application of epothilones in breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Microtubules; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Tubulin Modulators | 2008 |
Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms | 2008 |
Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Tubulin Modulators | 2008 |
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neutropenia; Peripheral Nervous System Diseases; Premedication; Tubulin Modulators | 2009 |
Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2010 |
Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Delivery Systems; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prodrugs | 2009 |
Emerging role of capecitabine in gastric cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis; Stomach Neoplasms | 2009 |
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Databases, Bibliographic; Deoxycytidine; DNA Mutational Analysis; Fluorouracil; Humans; Microsatellite Instability; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Treatment Outcome | 2009 |
Evolving treatment of advanced colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2009 |
Chemotherapy, which drugs and when.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Gemcitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Survival Analysis | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab | 2009 |
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Global Health; Humans; Immunosuppressive Agents; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Health Care Costs; Humans; Neoplasm Metastasis; Prodrugs | 2010 |
Evolution of systemic therapy for advanced pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Delivery Systems; Drug Design; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Survival | 2010 |
Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Design; Fluorouracil; Humans; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2010 |
Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Failure; Tubulin Modulators | 2010 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2011 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
Ixabepilone for the treatment of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].
Topics: Adenocarcinoma; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Positron-Emission Tomography; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2011 |
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Taxoids | 2011 |
Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2011 |
Update on chemotherapy in the treatment of urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Urinary Bladder Neoplasms | 2011 |
Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Bacteremia; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Pseudomonas Infections; Superinfection | 2011 |
Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Carcinoma; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic | 2012 |
Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2012 |
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2012 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Paracrine sonic hedgehog signaling derived from tumor epithelial cells: a key regulator in the pancreatic tumor microenvironment.
Topics: Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Fibroblasts; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Neuronal Plasticity; Paracrine Communication; Tumor Microenvironment | 2012 |
Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic | 2012 |
Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anthracyclines; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Models, Statistical; Neoadjuvant Therapy; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Risk Assessment; Taxoids; Treatment Outcome | 2013 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine-induced thrombotic microangiopathy].
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Thrombosis; Urologic Neoplasms; Vascular Diseases | 2002 |
Metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Autonomic Nerve Block; Celiac Plexus; Cholestasis; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Digestive System Diseases; Fluorouracil; Gastric Outlet Obstruction; Gemcitabine; Humans; Neoplasm Metastasis; Neuralgia; Palliative Care; Pancreatic Neoplasms; Risk Factors; Stents | 2002 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil | 2001 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prodrugs | 2002 |
Monotherapy options in the management of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2003 |
[Adjuvant treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Intraoperative Care; Metalloendopeptidases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organic Chemicals; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Phenylbutyrates; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Metastasis; Tegafur; United Kingdom; Uracil | 2003 |
Development of new agents for the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
Single-agent gemcitabine in the treatment of advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Quality of Life; Treatment Outcome | 2004 |
Gemcitabine and taxanes as a new standard of care in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2004 |
Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2004 |
Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2004 |
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Severity of Illness Index; Taxoids | 2003 |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Survival Rate; Taxoids; Treatment Outcome; United Kingdom | 2004 |
Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
Gemcitabine plus paclitaxel in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2005 |
Gemcitabine-taxane experience in the treatment of metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Remission Induction; Taxoids; Treatment Outcome | 2005 |
What is the best schedule for administration of gemcitabine-taxane?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Remission Induction; Taxoids; Trastuzumab | 2005 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Uracil; Vitamin B Complex | 2005 |
[Palliative chemotherapy of head and neck cancer: present status and future development].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Current therapies and advances in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Incidence; Neoplasm Metastasis; Pancreatic Neoplasms; Remission Induction; Vascular Endothelial Growth Factor A | 2006 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Gemcitabine: monochemotherapy of breast cancer.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
First line chemotherapy in advanced or metastatic NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoadjuvant Therapy; Neoplasm Metastasis | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Immunologic Factors; Neoplasm Metastasis; Trastuzumab | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
Safety of capecitabine use in patients with liver dysfunction.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms | 2007 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Death; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Tegafur; Treatment Outcome; Uracil; Vascular Endothelial Growth Factor A | 2007 |
Primary advanced unresectable pancreatic cancer.
Topics: Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Gemcitabine in the treatment of metastatic pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Neoplasm Metastasis; Pancreatic Neoplasms | 2008 |
Clinical studies with epothilones for the treatment of metastatic breast cancer.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Tubulin Modulators | 2008 |
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
Metastatic bladder cancer: advances in treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Urinary Bladder Neoplasms | 1997 |
Current and emerging treatments for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 1997 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Mitomycin; Neoplasm Metastasis; Nitrosourea Compounds; Pancreatic Neoplasms | 1998 |
Gemcitabine for palliative treatment in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Care | 1998 |
Gemcitabine in locally advanced and/or metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Urinary Bladder Neoplasms; Urothelium | 2000 |
New approaches to treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Gemcitabine as single-agent therapy in the management of advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Care | 2001 |
Treatment of advanced breast cancer with gemcitabine and vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2001 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Gemcitabine and Pemetrexed disodium in treating breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Neoplasm Metastasis; Pemetrexed | 2001 |
Second-line treatment of advanced transitional cell carcinoma of the urothelial tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium; Vinblastine | 2001 |
New chemotherapy combinations for advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Female; Gemcitabine; Humans; Male; Methotrexate; Neoplasm Metastasis; Platinum; Prognosis; Severity of Illness Index; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Dose scheduling--Herceptin.
Topics: Abdominal Muscles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Half-Life; Haplorhini; Humans; Infusions, Intravenous; Injections, Subcutaneous; Methotrexate; Neoplasm Metastasis; Paclitaxel; Safety; Trastuzumab; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
Topics: Absorption; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Interactions; Enzyme Induction; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Survival Analysis; Up-Regulation | 2001 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Paclitaxel; Patient Selection; Practice Guidelines as Topic; Research Design; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine doublets in advanced urothelial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Renal Insufficiency; Survival Analysis; Trastuzumab; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Novel gemcitabine-containing triplets in the management of urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms; Prodrugs | 2002 |
Overview: gemcitabine as single-agent therapy for advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Ribonucleotide Reductases; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine plus cisplatin for the treatment of metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids; Trastuzumab; Treatment Failure; Treatment Outcome | 2002 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Pyrimidines; Tegafur; Uracil | 2002 |
578 trial(s) available for deoxycytidine and Neoplasm Metastasis
| Article | Year |
|---|---|
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2021 |
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Time Factors | 2022 |
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbolines; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Research Design; Sarcoma | 2020 |
First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2020 |
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Global Health; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Analysis | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Topics: Adenocarcinoma; Aged; Albumins; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Progression-Free Survival; Radiation-Sensitizing Agents; Thrombocytopenia; Treatment Outcome | 2020 |
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2020 |
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2020 |
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2021 |
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers; Deoxycytidine; Disease Management; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Diseases; Kidney Function Tests; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Treatment Outcome | 2021 |
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2021 |
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Central Serous Chorioretinopathy; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dry Eye Syndromes; Fatigue; Female; Gemcitabine; Humans; Hyperphosphatemia; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrimidines; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Retinal Detachment; Safety; Stomatitis; Treatment Outcome | 2021 |
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Tegafur; Tomography, X-Ray Computed | 2017 |
Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neutropenia; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Survival Rate | 2017 |
Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Young Adult | 2017 |
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2018 |
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Republic of Korea; Time Factors; Treatment Outcome; Young Adult | 2017 |
"HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome; Young Adult | 2017 |
High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Cell Proliferation; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Parenteral; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Damage; DNA Mutational Analysis; Female; Gemcitabine; Humans; Ipilimumab; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Topics: Adult; Aged; Cancer Vaccines; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; T-Lymphocytes; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome | 2018 |
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quinolones; Treatment Outcome | 2018 |
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2018 |
[A Phase I Combination Dose-Escalation Study of Eribulin Mesylate and Gemcitabine in Japanese Patients with Metastatic Breast Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Furans; Gemcitabine; Humans; Ketones; Middle Aged; Neoplasm Metastasis | 2018 |
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2018 |
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Signal Transduction; Translational Research, Biomedical; Treatment Outcome | 2019 |
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Radiotherapy; Treatment Outcome | 2019 |
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Progression-Free Survival; Survival Rate | 2019 |
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Taiwan; Tegafur; Treatment Outcome | 2013 |
Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Patient Compliance; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Pharmacogenetics | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival; Survival Rate; Taxoids; Vitamin B Complex | 2013 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Republic of Korea; Young Adult | 2013 |
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Carboxylesterase; Deoxycytidine; Deoxyuridine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Polymorphism, Single Nucleotide; Prodrugs | 2013 |
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Proteinuria; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2013 |
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pancreatic Neoplasms; Prospective Studies; Survival; Young Adult | 2013 |
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Deoxycytidine; Gemcitabine; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Receptor, IGF Type 1; Survival Analysis | 2013 |
Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine | 2013 |
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Young Adult | 2013 |
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Cecum; Colon, Descending; Colon, Sigmoid; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum; Sigmoid Neoplasms; Survival; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2013 |
A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Quality-Adjusted Life Years; Survival Rate; Time Factors; Treatment Outcome | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Fluorouracil; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2013 |
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Treatment Failure; Uracil | 2014 |
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Salvage Therapy; Survival Rate | 2013 |
Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2013 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Estradiol; Female; Fluorouracil; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Leucovorin; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Treatment Outcome | 2014 |
Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Odds Ratio; Pilot Projects; Survival Analysis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Membrane Transport Proteins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2014 |
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2013 |
Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed | 2014 |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2014 |
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Netherlands; Polyethylene Glycols; Prospective Studies; Treatment Outcome | 2014 |
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Translational Research, Biomedical | 2014 |
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Vascular Access Devices | 2014 |
Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Isotope Labeling; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed | 2014 |
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2014 |
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Topics: Administration, Metronomic; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Treatment Outcome | 2014 |
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Time Factors; Treatment Outcome; Yttrium | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2014 |
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research G
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome | 2013 |
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2014 |
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate | 2014 |
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Prognosis; Pyridines; Survival Rate | 2014 |
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Lenalidomide; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Thalidomide; Urothelium | 2014 |
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Recombinant Proteins; Treatment Outcome | 2013 |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2014 |
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2014 |
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Deoxycytidine; Female; Gemcitabine; Hedgehog Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyridines; Signal Transduction; Treatment Outcome | 2014 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome | 2014 |
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids | 2014 |
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast; Breast Neoplasms; Cohort Studies; Deoxycytidine; Docetaxel; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Salvage Therapy; Survival Analysis; Taxoids | 2015 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Positron-Emission Tomography; Retreatment; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2014 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaloacetates; Predictive Value of Tests; Treatment Outcome | 2015 |
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Penile Neoplasms; Treatment Outcome | 2016 |
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2015 |
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Failure | 2015 |
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Middle Aged; Neoplasm Metastasis; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Uterine Neoplasms | 2015 |
A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2015 |
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Taxoids | 2015 |
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2015 |
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taiwan; Treatment Outcome | 2015 |
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2015 |
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma; Cisplatin; Cytokine-Induced Killer Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2015 |
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Fluorouracil; Humans; Intention to Treat Analysis; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Electroporation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mitomycin; Neoplasm Metastasis; Vascular Endothelial Growth Factor D | 2015 |
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mice, Knockout; Neoplasm Metastasis; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2015 |
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Protocols; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Translational Research, Biomedical | 2015 |
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2015 |
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retreatment; Survival Rate | 2016 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2018 |
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Endometrial Neoplasms; Female; Furans; Gemcitabine; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Ontario; Ovarian Neoplasms; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Treatment Outcome | 2016 |
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2016 |
Gemcitabine and Capecitabine Combination Chemotherapy in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and/or Taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2016 |
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cause of Death; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome | 2016 |
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Prospective Studies; Time Factors; Treatment Outcome | 2016 |
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2016 |
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2016 |
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Europe; Female; Gemcitabine; Humans; Immunotherapy, Active; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Deoxycytidine; Drug Monitoring; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Survival Analysis; Treatment Outcome | 2016 |
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2017 |
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2017 |
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Retrospective Studies | 2017 |
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Prospective Studies; Taxoids; Time Factors; Treatment Outcome | 2009 |
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Thrombocytopenia | 2007 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fever; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2008 |
A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine | 2008 |
Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2008 |
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate | 2008 |
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Tolerance; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids | 2008 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis | 2008 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Skin Diseases | 2008 |
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Deoxycytidine; Drug Interactions; Enoxaparin; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Pancreatic Neoplasms; Prospective Studies; Research Design; Survival Analysis; Swine; Venous Thromboembolism | 2008 |
A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2009 |
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2009 |
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur | 2009 |
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal; Rectal Neoplasms; Time Factors; Treatment Outcome | 2009 |
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2009 |
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Treatment Failure; Vascular Endothelial Growth Factor A | 2009 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2009 |
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2009 |
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2009 |
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic | 2009 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression; Humans; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Oligodeoxyribonucleotides; Organoplatinum Compounds; Oxaliplatin; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Vinblastine; Vinorelbine | 2009 |
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Drug Costs; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Taxoids | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate | 2009 |
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
Adjuvant chemotherapy in older women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Receptors, Estrogen; Survival Analysis | 2009 |
Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Japan; Kidney Diseases; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2009 |
Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Folic Acid; Health Care Costs; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Retrospective Studies; Treatment Outcome | 2009 |
Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Survival Analysis; Time Factors; Treatment Failure; Vinblastine; Vinorelbine | 2010 |
Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2009 |
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2009 |
Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Exanthema; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Pemetrexed; Pneumonia; Treatment Outcome | 2010 |
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2010 |
Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Sulfonamides; Toluene; Treatment Outcome | 2009 |
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2010 |
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Neoplasm Metastasis | 2010 |
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2010 |
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2011 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2009 |
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperati
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids; Time Factors | 2010 |
A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Treatment Outcome | 2010 |
Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2010 |
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Topics: Cyclin G1; Deoxycytidine; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Retroviridae | 2010 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Pilot Projects; Salvage Therapy; Survival Analysis; Thymus Neoplasms | 2010 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endpoint Determination; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids | 2010 |
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Gemcitabine; Humans; Irinotecan; Life Expectancy; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Piperidines | 2010 |
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Treatment Outcome; United States | 2010 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2010 |
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Prospective Studies; Recurrence; Stomach Neoplasms; Treatment Outcome | 2011 |
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Thymidine Phosphorylase; Thymidylate Synthase | 2010 |
Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis | 2010 |
Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Time Factors; Treatment Outcome; United States | 2010 |
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Thalidomide | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Analysis | 2010 |
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chicago; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Survival Analysis | 2011 |
A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2010 |
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Syndrome; Time Factors; Treatment Outcome | 2010 |
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Sensation Disorders; Treatment Outcome | 2010 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Treatment Outcome; Young Adult | 2011 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Platinum Compounds | 2010 |
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; China; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australasia; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Hypotension; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Quality of Life; Thrombocytopenia; Treatment Outcome | 2010 |
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2010 |
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Retreatment; Taxoids | 2010 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2010 |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Phenotype; Receptor, ErbB-2 | 2011 |
Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Salvage Therapy; Survival Rate; Uterine Cervical Neoplasms | 2010 |
Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2010 |
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Intention to Treat Analysis; Interferon-alpha; Interleukin-2; Italy; Kidney Neoplasms; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2010 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2011 |
Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis | 2010 |
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab | 2010 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Recurrence | 2011 |
Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Remission Induction; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Quality of Life | 2010 |
Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids; Young Adult | 2011 |
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2011 |
A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Pemetrexed; Recurrence; Squamous Cell Carcinoma of Head and Neck | 2011 |
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome | 2011 |
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Recurrence; Treatment Outcome | 2010 |
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Enhancer Elements, Genetic; Fluorouracil; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Multifactor Dimensionality Reduction; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Proportional Hazards Models; Thymidylate Synthase; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Thalidomide; Treatment Outcome | 2011 |
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis | 2011 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Vinblastine; Vinorelbine | 2010 |
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Carboplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis | 2011 |
Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2011 |
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Treatment Outcome | 2011 |
Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Taxoids; Thiotepa | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2011 |
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2011 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate | 2012 |
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors | 2011 |
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis | 2011 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2012 |
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2011 |
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2011 |
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cyclooxygenase 2; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Nucleoside Deaminases; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Ribonucleoside Diphosphate Reductase; Sorafenib; Tumor Suppressor Proteins | 2012 |
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Urologic Neoplasms; Vinblastine | 2011 |
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult | 2011 |
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2011 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Thymidylate Synthase | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis | 2011 |
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Germany; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life | 2012 |
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Capecitabine; Carcinoma, Renal Cell; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Etoricoxib; Female; Fluorouracil; Follow-Up Studies; Humans; Hypoglycemic Agents; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pioglitazone; Prognosis; Prospective Studies; Pyridines; Sulfones; Survival Rate; Thiazolidinediones | 2012 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2012 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Diseases; Treatment Outcome | 2011 |
Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Treatment Outcome | 2012 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cell Count; Colorectal Neoplasms; Deoxycytidine; Endothelial Cells; Endothelium, Vascular; Female; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Metastasis; Quality of Life | 2011 |
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Treatment Outcome | 2012 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2011 |
A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Dyspnea; Fatigue; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2012 |
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Phosphorylcholine | 2011 |
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Retreatment; Treatment Outcome | 2011 |
Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Agents; Bevacizumab; Blood Platelets; CD146 Antigen; Deoxycytidine; Drug Administration Schedule; Endothelial Cells; Female; Flow Cytometry; Gemcitabine; Humans; Immunophenotyping; Leukocyte Common Antigens; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Regression Analysis; T-Lymphocytes; Treatment Outcome | 2011 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine | 2012 |
Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Quality of Life; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids | 2011 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Placebos; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk | 2012 |
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Treatment Outcome | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Pulmonary Embolism; Quinazolines; Treatment Outcome | 2012 |
A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Proton Therapy | 2012 |
Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Prognosis; Prospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging | 2012 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Survival Rate | 2011 |
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2012 |
Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Thailand; Treatment Outcome | 2012 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies | 2012 |
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Salvage Therapy; Trastuzumab; Vinblastine; Vinorelbine | 2012 |
A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy | 2012 |
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2 | 2012 |
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2012 |
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2012 |
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2012 |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Odds Ratio; Survival Rate; Taxoids; Treatment Outcome; Tubulin Modulators | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Colorectal Neoplasms; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal | 2012 |
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Placebos; Receptor, IGF Type 1; Survival Rate; Treatment Outcome | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteopontin; Treatment Outcome | 2012 |
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Trastuzumab | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2012 |
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; France; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Lenograstim; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Uterine Neoplasms | 2012 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Pyridines; Quinazolines; Survival Analysis | 2012 |
Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult | 2012 |
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids | 2012 |
Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase; Tubulin; Vinblastine; Young Adult | 2013 |
[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Quality of Life; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Prospective Studies; Survival Rate | 2013 |
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2013 |
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms | 2013 |
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2013 |
Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Randomized Controlled Trials as Topic | 2013 |
Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Treatment Outcome | 2013 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2 | 2013 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Sample Size; Survival Analysis | 2013 |
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Constipation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2013 |
All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Thalidomide | 2013 |
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Taxoids | 2013 |
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Half-Life; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Molecular Structure; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Thrombocytopenia | 2002 |
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flutamide; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Treatment Outcome | 2002 |
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Karnofsky Performance Status; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pancreatic Neoplasms; Recombinant Proteins; Treatment Outcome | 2002 |
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia; Treatment Outcome; Tumor Cells, Cultured | 2003 |
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Adenoviridae; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; In Situ Hybridization; Injections, Intralesional; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Safety; Treatment Outcome; Ultrasonography; Viral Vaccines | 2003 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Heart Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Salvage Therapy; Soft Tissue Neoplasms | 2003 |
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival; Treatment Outcome | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
Gemcitabine and trastuzumab in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2003 |
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Pilot Projects | 2003 |
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Organic Chemicals; Pancreatic Neoplasms; Phenylbutyrates; Proportional Hazards Models; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 5; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Phosphoric Diester Hydrolases; Prodrugs; Sulindac | 2003 |
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunologic Factors; Immunotherapy; Interferon-gamma; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins | 2003 |
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Peripheral Nervous System Diseases; Safety | 2003 |
Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2004 |
Impact of Gemcitabine and Cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Urinary Bladder Neoplasms | 2003 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain | 2004 |
Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Selection; Survival Rate; Treatment Outcome; World Health Organization | 2003 |
Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection; Salvage Therapy; Survival Analysis; Trastuzumab; Treatment Outcome; World Health Organization | 2003 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab; Treatment Outcome | 2003 |
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids; Treatment Outcome | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Injections, Intravenous; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Analysis; Treatment Outcome | 2004 |
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Hormones; Humans; Male; Middle Aged; Neoplasm Metastasis; Prodrugs; Prostatic Neoplasms; Quality of Life; Survival Analysis | 2004 |
Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Taxoids; Treatment Outcome | 2004 |
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; United States | 2004 |
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Taxoids | 2004 |
Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Risk Factors; Survival Analysis; Trastuzumab; Treatment Outcome | 2004 |
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Radiometry; Time Factors; Treatment Outcome | 2004 |
Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Treatment Outcome | 2004 |
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, Transitional Cell; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Kidney Function Tests; Life Tables; Male; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids | 2004 |
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Nail Diseases; Neoplasm Metastasis; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2004 |
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Neoplasm Metastasis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids | 2004 |
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pancreatic Neoplasms; Quality of Life; Severity of Illness Index; Taxoids | 2004 |
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphorothioate Oligonucleotides; Survival Analysis | 2004 |
Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Italy; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Genetic; Prognosis; Prospective Studies; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2005 |
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Patient Selection; Prodrugs; Safety | 2005 |
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2005 |
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Greece; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Risk Assessment; Survival Analysis; Terminally Ill; Treatment Outcome | 2005 |
Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2005 |
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study.
Topics: Aged; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause | 2005 |
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Italy; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2005 |
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; Treatment Outcome | 2005 |
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2005 |
Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Injections, Intra-Arterial; Injections, Intravenous; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Deoxycytidine; Female; Gemcitabine; Heart Diseases; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2005 |
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2005 |
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Uveal Neoplasms | 2005 |
Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2005 |
Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer.
Topics: Adult; Aged; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes | 2005 |
Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2006 |
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Pemetrexed; Survival Analysis | 2006 |
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Odds Ratio; Remission Induction; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Pyridines; Tegafur; Time Factors; Treatment Outcome | 2005 |
Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2005 |
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids | 2005 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Thalidomide; Treatment Outcome | 2006 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Salvage Therapy; Survival Analysis; Thiophenes | 2006 |
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Fatigue; Female; Fluorouracil; Folic Acid; Homocysteine; Humans; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Survival Analysis | 2006 |
Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pneumonia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis | 2006 |
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2006 |
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Aged; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur; Time Factors | 2006 |
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Recurrence; Severity of Illness Index; Stomatitis; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome | 2007 |
Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2006 |
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Analysis; Time Factors; Urinary Bladder Neoplasms; Vinblastine | 2006 |
Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Quality of Life | 2006 |
Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Vinblastine; Vinorelbine | 2006 |
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 2006 |
A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Survival Analysis; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2006 |
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Survival Rate | 2006 |
Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2006 |
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Compliance | 2006 |
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2006 |
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prodrugs; Sample Size; Survival Analysis; Treatment Outcome | 2007 |
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
[Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Pelvis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2006 |
Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Taxoids | 2006 |
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Analysis; Treatment Outcome | 2006 |
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Prodrugs; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Recurrence; Survival Analysis | 2007 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Treatment Outcome | 2007 |
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blood Cell Count; Capecitabine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms; Treatment Outcome | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vinblastine; Vinorelbine | 2007 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Male; Neoplasm Metastasis; Survival Analysis; Urinary Bladder Neoplasms; Urothelium | 2007 |
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 2008 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Camptothecin; Cyclin A; Deoxycytidine; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Fluorouracil; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Survival Analysis | 2008 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Stomach Neoplasms; Survival Analysis | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Spain; Treatment Outcome | 2007 |
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prodrugs; Remission Induction; Survival Rate; Treatment Failure | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome | 2007 |
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Taxoids; Treatment Outcome | 2007 |
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2006 |
Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2007 |
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Glycoproteins; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Peptides; Prognosis; Protein Kinase C; Protein Kinase C beta; RNA, Messenger; Survival Rate | 2007 |
Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2007 |
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Vinblastine; Vinorelbine | 2008 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Metastasis; Recombinant Proteins; Thalidomide | 2008 |
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase | 2008 |
Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2007 |
Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum Compounds; Survival Rate; Treatment Outcome | 2008 |
Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Survival Analysis | 2007 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis | 2007 |
Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pyridines; Salvage Therapy; Survival Analysis | 2007 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2007 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Rectal Neoplasms | 2007 |
[Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2007 |
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate | 2008 |
Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2008 |
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Compliance; Survival Analysis | 2008 |
Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2008 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab | 2008 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pemetrexed; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vitamin B 12; Vitamin B Complex | 2008 |
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome | 2008 |
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A | 2008 |
Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.
Topics: Adult; Aged; CA-19-9 Antigen; Cyclin G; Cyclin G1; Cyclins; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retroviridae; Stem Cells; Treatment Outcome | 2008 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Placebos | 2008 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Time Factors; Treatment Failure | 2008 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Texas; Thalidomide; Treatment Outcome | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Recurrence; Treatment Outcome | 2008 |
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2009 |
Advanced breast cancer: a phase II trial with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Remission Induction; Vomiting | 1995 |
Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms | 1994 |
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Ribonucleotide Reductases; Treatment Outcome; Vomiting | 1997 |
Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1997 |
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1997 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Survival Rate; Time Factors | 1999 |
Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis | 1999 |
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pemetrexed | 1999 |
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Platelet Count; Vinblastine; Vinorelbine | 2000 |
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed | 2000 |
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 2000 |
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2000 |
Capecitabine in the treatment of metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Isotretinoin; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Treatment Outcome | 2000 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Europe; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Failure; United States | 2000 |
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hospitalization; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quality of Life; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis | 2000 |
Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2000 |
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome; Vomiting | 2000 |
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Patient Acceptance of Health Care; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Gemcitabine plus cisplatin in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis | 2001 |
Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2001 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2001 |
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2001 |
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heart; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Palliative Care; Taxoids; Treatment Failure | 2001 |
Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy | 2001 |
Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Remission Induction; Safety; Vomiting | 2001 |
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome | 2001 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Hematuria; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Urination Disorders; Urologic Neoplasms | 2001 |
Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Vinblastine; Vinorelbine | 2002 |
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Consumer Product Safety; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Survival Analysis | 2002 |
Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pain Measurement; Receptors, Estrogen; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2002 |
Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Survival Rate; Time Factors | 2002 |
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2002 |
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids | 2002 |
A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2002 |
[Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Recurrence | 2002 |
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2002 |
Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis; Trastuzumab; Treatment Failure; Treatment Outcome | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
436 other study(ies) available for deoxycytidine and Neoplasm Metastasis
| Article | Year |
|---|---|
Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chondroitin Sulfates; Delayed-Action Preparations; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Hydrogels; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice, Inbred BALB C; Micelles; Neoplasm Metastasis; Poloxamer; Tryptophan; Tumor Microenvironment | 2021 |
Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors | 2022 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Diet, Ketogenic; Female; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia, Induced; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survivors | 2020 |
First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2019 |
Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Green Fluorescent Proteins; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms | 2019 |
Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Compounding; Drug Design; ErbB Receptors; Female; Gemcitabine; Humans; Liposomes; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Polyethylene Glycols; Protein Kinase Inhibitors; Proteolysis; Xenograft Model Antitumor Assays | 2019 |
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunoglobulin G; Inflammation; Interleukin-1beta; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; THP-1 Cells; Xenograft Model Antitumor Assays | 2019 |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Knockdown Techniques; Humans; Integrin alpha3; Integrin beta1; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; Spheroids, Cellular; STAT3 Transcription Factor; Survival Rate; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2020 |
Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doublecortin-Like Kinases; Gemcitabine; Hepatocyte Growth Factor; Humans; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Mice; Neoplasm Metastasis; Neoplasm Staging; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Pancreatic Stellate Cells; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-met; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Middle Aged; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2020 |
The economic burden of metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost of Illness; Costs and Cost Analysis; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Health Resources; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Needs Assessment; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.
Topics: Animals; Breast Neoplasms; Deoxycytidine; Drug Combinations; Drug Delivery Systems; Female; Gemcitabine; Kidney; Liver; Lung; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Spleen; Tissue Distribution | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
Chemotherapy combined with apatinib for the treatment of desmoplastic small round cell tumors: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Desmoplastic Small Round Cell Tumor; Epirubicin; Gemcitabine; Humans; Male; Neoplasm Metastasis; Oncogene Proteins, Fusion; Pyridines; RNA-Binding Protein EWS; Treatment Outcome; Vincristine; WT1 Proteins | 2020 |
Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Lung Neoplasms; Metabolomics; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Retinal Dehydrogenase | 2021 |
Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Macrophages; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Microenvironment | 2020 |
Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.
Topics: Afatinib; Animals; Cell Line, Tumor; Deoxycytidine; ErbB Receptors; Gemcitabine; Hepatocyte Nuclear Factor 3-beta; Humans; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; SOX9 Transcription Factor | 2021 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Autophagy; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; Urinary Bladder Neoplasms | 2021 |
Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Gemcitabine; Humans; MAP Kinase Signaling System; Neoplasm Metastasis; Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins p21(ras); ras Proteins; Thiazolidines; Wnt Signaling Pathway | 2021 |
First-line Gemcitabine
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Physicians; Prospective Studies; Quality of Life; Treatment Failure | 2021 |
AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.
Topics: Animals; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Plasticity; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment | 2021 |
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur | 2021 |
Abdominal Wall Metastasis of Pancreatic Cancer: The Tip of the Iceberg-Case Report.
Topics: Abdominal Wall; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2021 |
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Internationality; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus; Dietary Supplements; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3 beta; Glycolysis; Humans; Inhibitory Concentration 50; Malaria; MCF-7 Cells; Metformin; Molecular Targeted Therapy; Neoplasm Metastasis; Nitrophenols; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thiadiazoles; Tumor Stem Cell Assay | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score | 2021 |
A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Depsipeptides; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Reactive Oxygen Species; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2021 |
Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Phenotype | 2021 |
Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2021 |
Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chitosan; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Nanoparticles; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Biosensing Techniques; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Collagen; Deoxycytidine; Disease Progression; Extracellular Matrix; Gemcitabine; Humans; Liver; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; rho-Associated Kinases; Signal Transduction; src-Family Kinases; Treatment Outcome | 2017 |
[Comparison of Preparation Efficiency and Therapeutic Safety between Generic Products of Gemcitabine].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drugs, Generic; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Thrombocytopenia; Vomiting | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Cost of Illness; Deoxycytidine; Drug Costs; Female; Filgrastim; Fluorouracil; Gemcitabine; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors | 2017 |
Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.
Topics: Adenocarcinoma; Animals; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Hepatocyte Growth Factor; Humans; Imidazoles; Mice; Mice, Transgenic; Neoplasm Metastasis; Proto-Oncogene Proteins c-met; Pyridines; Triazines; Tumor Microenvironment | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Registries; Retrospective Studies; Saskatchewan; Survival Rate; Travel | 2017 |
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Maintenance Chemotherapy; Neoplasm Metastasis; Peritoneal Neoplasms; Splenic Neoplasms; Time Factors; Treatment Outcome | 2017 |
CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGA2 Protein; Humans; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Receptors, CXCR4 | 2017 |
Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Demography; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2017 |
Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Capecitabine; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Hospitals, Public; Humans; Models, Theoretical; Neoplasm Metastasis; Oxaloacetates; Treatment Outcome | 2017 |
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Receptor, ErbB-2; Receptors, Estrogen; Retreatment; Trastuzumab; Treatment Outcome | 2018 |
Metastatic Collecting (Bellini) Duct Carcinoma Presented in a Young Patient: A Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Ductal; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Iliac Vein; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiography, Abdominal; Spleen; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2017 |
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Glycoproteins; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptors, Immunologic; RNA Interference; Transcription Factor AP-2; Xenograft Model Antitumor Assays | 2018 |
A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms | 2018 |
miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer.
Topics: Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; MicroRNAs; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured; Tumor Hypoxia | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Gemcitabine plus S-1 for metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2018 |
Dihomo-γ-linolenic acid inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Delta-5 Fatty Acid Desaturase; Deoxycytidine; Disease Models, Animal; Drug Synergism; Fatty Acid Desaturases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2019 |
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Recombinant Proteins; Thymoma; Thymus Neoplasms; Uganda | 2019 |
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Sodium; Survival Analysis; Treatment Outcome; Venous Thromboembolism | 2018 |
Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Treatment Outcome | 2019 |
Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Heterografts; Humans; Leiomyosarcoma; Mice; Mice, Nude; Neoplasm Metastasis; Peritoneal Neoplasms; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Burden | 2019 |
Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Endopeptidases; Gelatinases; Gemcitabine; Humans; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; PC-3 Cells; Prodrugs; Rats, Sprague-Dawley; Serine Endopeptidases; Tumor Microenvironment | 2019 |
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Celiac Artery; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Splenic Artery; Time Factors; Treatment Failure; Tumor Burden | 2019 |
Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms | 2018 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2018 |
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Topics: Albumins; Biomarkers; Breast Neoplasms; Caveolin 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel | 2019 |
Topics: Animals; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Copper Radioisotopes; Deoxycytidine; Disease Models, Animal; ErbB Receptors; Female; Gemcitabine; HCT116 Cells; Humans; Injections, Intraperitoneal; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Radioimmunotherapy; Radiotherapy, Adjuvant; Treatment Outcome | 2019 |
WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction; WT1 Proteins | 2019 |
Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Recurrence; Treatment Outcome; Young Adult | 2019 |
Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Fendiline; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphoproteins; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Verteporfin; YAP-Signaling Proteins | 2019 |
Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination.
Topics: Adenocarcinoma; Albumins; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Hepatocyte Nuclear Factor 1-alpha; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Protein Binding | 2019 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Humans; Male; Markov Chains; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retreatment; Retrospective Studies | 2020 |
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
Topics: Aged; Biomarkers, Pharmacological; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Association Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2013 |
[Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Treatment Outcome; Urologic Neoplasms | 2013 |
Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma in Situ; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Polycomb Repressive Complex 1; Xenograft Model Antitumor Assays | 2013 |
Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Survival Analysis; Treatment Outcome | 2013 |
Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Rectal Neoplasms; Remission Induction; Treatment Outcome | 2013 |
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camptothecin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Tissue Scaffolds; Xenograft Model Antitumor Assays | 2013 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2013 |
Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization; Male; MicroRNAs; Microvessels; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Oxaloacetates; Prognosis; Young Adult | 2013 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
Downregulation of LIMK1 level inhibits migration of lung cancer cells and enhances sensitivity to chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lim Kinases; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Respiratory Mucosa; RNA, Small Interfering | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Oxaloacetates; Retrospective Studies; Survival Analysis | 2013 |
[Clinical experience with gemcitabine treatment for metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quality of Life; Recurrence | 2013 |
Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cellular Senescence; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-raf; Retinoblastoma Protein; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2013 |
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; ROC Curve; Survival Analysis; Treatment Outcome | 2013 |
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postoperative Period; Preoperative Period; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Bleeding from gastrointestinal tract recurrence of non-seminomatous germ cell tumour testis, showing temporary response to gemcitabine and oxaliplatin chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Radiography; Testicular Neoplasms; Thalidomide; Thrombocytopenia | 2013 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2014 |
Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gemcitabine; Gene Expression; Glycoproteins; Humans; Immunophenotyping; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Phenotype; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2013 |
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2014 |
[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Postoperative Period; Radiotherapy, Conformal; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; Humans; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaloacetates; Pharmacogenetics; Polymorphism, Single Nucleotide; Recurrence; Retrospective Studies | 2014 |
[Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates | 2013 |
[A case in which chemotherapy-resistant sigmoid colon cancer was controlled effectively by radiotherapy and resection].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Recurrence; Sigmoid Neoplasms | 2013 |
Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2014 |
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prodrugs; Prognosis; Survival Rate | 2014 |
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Treatment Outcome | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Lactate Dehydrogenases; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2014 |
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Rectum; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Oral chemotherapy in elderly women with metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Idarubicin; Infusions, Intravenous; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2014 |
Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Erythrocyte Indices; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Deoxycytidine; Enzyme Inhibitors; Female; Fibrinolytic Agents; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Tinzaparin; Xenograft Model Antitumor Assays | 2014 |
Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported?
Topics: Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Recurrence | 2015 |
Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Erythrocyte Indices; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2013 |
RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); rac1 GTP-Binding Protein; ras Proteins | 2014 |
Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Models, Animal; Female; Gastrointestinal Hormones; Gemcitabine; Humans; Mice; Neoplasm Metastasis; Neuropeptides; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; NIH 3T3 Cells; Pancreatic Neoplasms; Random Allocation; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2014 |
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Community Health Services; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States; Young Adult | 2014 |
NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; Cytotoxicity, Immunologic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Retrospective Studies | 2014 |
Phase 1 trials in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2014 |
[Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Recurrence; Retrospective Studies; Treatment Outcome | 2014 |
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression; Humans; Immunohistochemistry; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Stomach Neoplasms; Thymidylate Synthase; Treatment Outcome | 2014 |
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Argininosuccinate Synthase; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Hydrolases; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Signal Transduction; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; MicroRNAs; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pseudogenes; PTEN Phosphohydrolase; RNA Interference; RNA, Messenger; Tumor Burden | 2014 |
Silencing of STRN4 suppresses the malignant characteristics of cancer cells.
Topics: Animals; Anoikis; Calmodulin-Binding Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms, Experimental; Nerve Tissue Proteins; Pancreatic Neoplasms; RNA, Small Interfering | 2014 |
Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Diphosphonates; Gemcitabine; Humans; Imidazoles; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Perioperative Care; Proportional Hazards Models; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Germany; Hormones; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine; Young Adult | 2014 |
Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neoplasm Metastasis; Survival Rate; Vitamin B Complex | 2014 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Capecitabine; Carcinoma; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2014 |
3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Deoxycytidine; Dideoxynucleosides; Female; Gemcitabine; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Genotype; Germ-Line Mutation; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Predictive Value of Tests; Thymidylate Synthase | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Gemcitabine + platinum combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Diseases; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Turkey | 2014 |
Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2015 |
[A case of metastatic rectal cancer with fulminant hepatitis caused by XELOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hepatitis; Humans; Male; Neoplasm Metastasis; Oxaloacetates; Rectal Neoplasms | 2014 |
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Topics: Adult; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis; United Kingdom | 2015 |
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis | 2015 |
[Efficacy of neoadjuvant chemotherapy for pancreatic carcinoma planned resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Uracil | 2015 |
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Spain | 2015 |
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Renal Cell; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Protein-Lysine 6-Oxidase; Treatment Outcome | 2015 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2015 |
Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2015 |
miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer.
Topics: Cell Line; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Metastasis; Pancreatic Neoplasms; Promoter Regions, Genetic; Transforming Growth Factor beta; Ubiquitin-Protein Ligases | 2015 |
Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Deoxycytidine; Diagnostic Imaging; Drug Delivery Systems; Fluorescent Dyes; Gemcitabine; HEK293 Cells; Humans; Hypoxia; Male; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Organic Anion Transporters; Prostatic Neoplasms; Spectroscopy, Near-Infrared; Xenograft Model Antitumor Assays | 2015 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Child; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Prognosis; Retroperitoneal Neoplasms; Salvage Therapy; Survival Rate; Testicular Neoplasms; Transplantation, Autologous; Young Adult | 2015 |
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Specific Pathogen-Free Organisms; Warfarin; Xenograft Model Antitumor Assays | 2015 |
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleoside Transport Proteins; Pancreatic Neoplasms; Snail Family Transcription Factors; Survival Analysis; Transcription Factors; Twist-Related Protein 1 | 2015 |
Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Hepatocyte Growth Factor; Humans; Inhibitor of Differentiation Protein 1; Mice; Neoplasm Metastasis; Nicotine; Pancreatic Neoplasms; Paracrine Communication; Phosphorylation; Proto-Oncogene Proteins c-met; Signal Transduction; Smoking; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Middle Aged; Molecular Chaperones; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Retrospective Studies; Survival Rate | 2016 |
The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Frequency; HLA-B27 Antigen; HLA-DRB1 Chains; Humans; Infusions, Intravenous; Japan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Young Adult | 2016 |
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Receptors, Interleukin-8B; Signal Transduction; Small Molecule Libraries; Survival Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
GEMOX: An Active Regimen for the Treatment of Luminal and Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2017 |
Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; Retreatment; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature.
Topics: Adult; Breast Neoplasms; Carboplatin; Carcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Medicine | 2016 |
GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
Topics: Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Binding; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tissue Array Analysis | 2016 |
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Histocompatibility Antigens; Histone Demethylases; Histone-Lysine N-Methyltransferase; Humans; Interleukin-8; Male; Mice; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, Interleukin-8A; RNA, Small Interfering | 2016 |
The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer.
Topics: Adult; Antineoplastic Agents; Asian People; Canada; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mutation; Neoplasm Metastasis; Pemetrexed; Philippines; Reactive Oxygen Species; Treatment Outcome | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Compassionate Use Trials; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Preoperative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Analysis | 2016 |
Repeated iodine-125 seed implantations combined with external beam radiotherapy for the treatment of locally recurrent or metastatic stage III/IV non-small cell lung cancer: a retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiotherapy; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: The AGEVIM multicenter cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Neoplasm Metastasis; Prospective Studies; Serum Albumin; Survival Rate; Time Factors; Tumor Burden; Urinary Bladder Neoplasms; Withholding Treatment | 2017 |
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms; Venous Thromboembolism | 2017 |
Prognostic Differences: Epstein-Barr Virus-Associated Primary Leiomyosarcoma of the Spine Versus Spinal Leiomyosarcoma Metastases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Docetaxel; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunocompromised Host; Leiomyosarcoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Prognosis; Retroperitoneal Neoplasms; Spinal Neoplasms; Taxoids | 2017 |
Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Databases, Factual; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2017 |
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Survival Analysis; Treatment Outcome | 2017 |
[Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Recurrence; Treatment Outcome | 2016 |
[A Long-Surviving Case of Unresectable Gall Bladder Carcinoma Treated with Gemcitabine-Based Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Time Factors | 2016 |
Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.
Topics: Aged; alpha Karyopherins; Antineoplastic Agents; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Transport; RNA Interference; Tumor Burden | 2017 |
Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
Topics: Aerobiosis; Carcinogenesis; Cell Line, Tumor; Deoxycytidine; Doublecortin-Like Kinases; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycolysis; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Up-Regulation | 2017 |
Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2008 |
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Thymidine Phosphorylase; Time Factors; Treatment Outcome; Ubiquitin-Protein Ligases | 2009 |
Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Movement; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Down-Regulation; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Radiography; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Remission Induction; Treatment Outcome | 2008 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Retrospective Studies; Taxoids; Urologic Neoplasms; Vinblastine | 2008 |
Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Clusterin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Metastasis; Oligonucleotides, Antisense; Thionucleotides; Urinary Bladder Neoplasms | 2009 |
[Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous cystic neoplasm of the pancreas].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cystadenoma, Mucinous; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiography | 2008 |
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2008 |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity | 2009 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dog Diseases; Dogs; Female; Gemcitabine; Infusions, Intravenous; Mammary Neoplasms, Animal; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2008 |
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, Transgenic, Suicide; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Survival Analysis | 2009 |
[Retrospective analysis of uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy in unresectable pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leukopenia; Life Tables; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Patient Selection; Prognosis; Survival Analysis; Time Factors | 2009 |
Advancements in the management of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Muscle, Skeletal; Muscular Diseases; Neoplasm Metastasis; Prospective Studies | 2009 |
Lapatinib: new drug. For some women with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Female; Fluorouracil; France; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2009 |
Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids | 2009 |
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Monitoring; Fluorouracil; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Sex Distribution | 2009 |
[Palliative chemotherapy for metastatic breast cancer with capecitabine].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2009 |
Cancer. Breaching the cancer fortress.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Fibroblasts; Gemcitabine; Hedgehog Proteins; Humans; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Signal Transduction; Stromal Cells | 2009 |
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Curcumin; Cyclin D1; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; NF-kappa B; Receptors, CXCR4; Vascular Endothelial Growth Factor A | 2009 |
A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Radiation-Sensitizing Agents; Treatment Outcome | 2009 |
Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2009 |
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms | 2009 |
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Hot Temperature; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Time Factors; Treatment Outcome | 2010 |
Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Capillary Permeability; Cell Line, Tumor; Cells, Cultured; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Liposomes; Luciferases; Male; Mice; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Transduction, Genetic; Xenograft Model Antitumor Assays | 2009 |
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Neoplasm Metastasis; Pyridoxine; Retrospective Studies; Vitamin B Complex | 2010 |
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Neoplasm Metastasis | 2010 |
Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Chemistry, Pharmaceutical; Cytarabine; Deoxycytidine; Docetaxel; Drug Design; Drug Screening Assays, Antitumor; Fatty Acids; Humans; Inhibitory Concentration 50; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2010 |
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2010 |
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromosome Mapping; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Rectal Neoplasms; Tumor Suppressor Proteins | 2010 |
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2010 |
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Haplotypes; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Polymorphism, Single Nucleotide; Predictive Value of Tests; Vascular Endothelial Growth Factor A | 2011 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2010 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure | 2011 |
Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2010 |
[More effective positioning of capecitabine for advanced and metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2; Survival Rate | 2010 |
Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
Topics: Age Factors; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Health Expenditures; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Sex Factors | 2010 |
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Drug Recalls; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2010 |
[Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Receptors, Estrogen; Survival Analysis | 2010 |
Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Indoles; Inhibitory Concentration 50; Kaplan-Meier Estimate; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Red Fluorescent Protein; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2011 |
Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclin D1; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Matrix Metalloproteinase 9; Mice; Nanoparticles; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Polymers; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Esophageal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2010 |
Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Salvage Therapy; Thrombotic Microangiopathies | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2011 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Care Costs; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models | 2010 |
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Movement; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Endothelium, Vascular; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Shiga Toxins; Signal Transduction; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Pharmacogenetics; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2010 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Blood Cell Count; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemoglobins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Patient Selection | 2010 |
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate | 2011 |
A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy Dosage; Retrospective Studies | 2011 |
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2011 |
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.
Topics: Adult; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; France; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2011 |
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neuropilin-1; Vascular Endothelial Growth Factor C | 2011 |
[Our experiences of XELOX + bevacizumab for two cases of metastatic sigmoid colon cancer].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Oxaloacetates; Quality of Life; Sigmoid Neoplasms | 2010 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Colostomy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Proportional Hazards Models; Pyrimidines; Radiotherapy, Adjuvant; Survival Rate | 2011 |
Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Salvage Therapy; Statistics, Nonparametric; Treatment Outcome | 2012 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Epidemiologic Methods; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2011 |
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Metabolome; Metabolomics; Middle Aged; Neoplasm Metastasis; Nuclear Magnetic Resonance, Biomolecular; Prognosis; Salvage Therapy | 2011 |
Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Retinal Vein Occlusion; Risk Factors; Vision Disorders | 2012 |
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Fluorouracil; Humans; Models, Theoretical; Neoplasm Metastasis; Taxoids | 2011 |
Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2011 |
Novel approaches to treatment of leiomyosarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Molecular Targeted Therapy; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Taxoids | 2011 |
[The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms | 2011 |
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Smad4 Protein; Statistics as Topic; Statistics, Nonparametric | 2011 |
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Clusterin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Neoplasm Metastasis; RNA Interference; Taxoids; Transcription, Genetic | 2012 |
Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urothelium | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure | 2012 |
Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2011 |
Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2011 |
c-Met is a marker of pancreatic cancer stem cells and therapeutic target.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Therapy, Combination; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines | 2011 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Triterpenes; Xenograft Model Antitumor Assays | 2011 |
Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; France; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies; Tegafur; Vitamin B Complex | 2012 |
[Experience with gemcitabine monotherapy in three patients with metastatic urothelial carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Disease-Free Survival; Erythrocyte Volume; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Thymidylate Synthase; Treatment Outcome; Young Adult | 2012 |
Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes.
Topics: Aged; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis | 2013 |
Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2011 |
Current treatment options for metastatic breast cancer: what now?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Tubulin Modulators | 2011 |
The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Genotype; Humans; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Prognosis; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells.
Topics: Basigin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocarboxylic Acid Transporters; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Symporters | 2012 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Retrospective Studies | 2012 |
Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gene Expression; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Taxoids; Thymidine Phosphorylase; Tubulin | 2012 |
Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies | 2012 |
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Outcome Assessment; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Symptom Assessment | 2013 |
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fluorouracil; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Neoplasm Metastasis; NF-kappa B; Platelet Endothelial Cell Adhesion Molecule-1; Signal Transduction; STAT3 Transcription Factor; Triterpenes; Tumor Suppressor Proteins; Ursolic Acid; Xenograft Model Antitumor Assays | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Effectiveness of oxaliplatin desensitization protocols.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Desensitization, Immunologic; Drug Hypersensitivity; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Skin Tests | 2013 |
Oncologically safe distal resection margins in rectal cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cross-Sectional Studies; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
Topics: Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fluorouracil; Humans; Indoles; MicroRNAs; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Renal Insufficiency; Urologic Neoplasms; Urothelium | 2013 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2012 |
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Databases as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Models, Statistical; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2012 |
Treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Platinum | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Tumor size as measured at initial X-ray examination, not length of bile duct stricture, predicts survival in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Bile Ducts; Cholangiopancreatography, Endoscopic Retrograde; Constriction, Pathologic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Intermediate Filament Proteins; Mice; Mice, SCID; Neoplasm Metastasis; Nerve Tissue Proteins; Nestin; Octamer Transcription Factor-3; Pancreatic Neoplasms; Polymerase Chain Reaction; Stem Cells | 2013 |
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates | 2012 |
Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Furans; Humans; Ketones; Markov Chains; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2012 |
Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Alleles; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Genomic Instability; Glycoproteins; GPI-Linked Proteins; Humans; Isoenzymes; Keratins; Male; Mesothelin; Mice; Middle Aged; Mutation; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Polyploidy; Retinal Dehydrogenase; Transplantation, Heterologous; Tumor Microenvironment | 2012 |
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.
Topics: Animals; Cell Communication; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Tolerance; Macrophages; Mice; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Receptor, Macrophage Colony-Stimulating Factor; Receptors, CCR2; STAT3 Transcription Factor; T-Lymphocytes, Cytotoxic | 2013 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Topics: Acute Disease; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Male; Neoplasm Metastasis; Neutropenia; Pancreatitis; Pyrroles; Sunitinib; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2013 |
[Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Steroid | 2012 |
Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kidney Diseases; Kidney Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Risk Assessment; Treatment Outcome | 2002 |
Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Photosensitivity Disorders; Prodrugs | 2002 |
Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Program Evaluation; Treatment Outcome; United Kingdom | 2002 |
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cells; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2002 |
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Kidney; Lung; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Prodrugs; Randomized Controlled Trials as Topic | 2001 |
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
Topics: Animals; Camptothecin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2003 |
[Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed | 2003 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report.
Topics: Biopsy, Needle; Capillary Leak Syndrome; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Pulmonary Edema; Risk Assessment; Severity of Illness Index | 2003 |
Capecitabine: new indication. In breast cancer: inadequately assessed.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Drug Approval; Drug Evaluation; European Union; Female; Humans; Neoplasm Metastasis; Treatment Outcome | 2003 |
A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Luminescent Proteins; Male; Mice; Mice, Nude; Models, Animal; Neoplasm Metastasis; Pancreatic Neoplasms; Predictive Value of Tests; Red Fluorescent Protein; Transduction, Genetic; Tumor Cells, Cultured | 2003 |
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Palliative Care; Vinblastine; Vinorelbine | 2003 |
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Thymidine Phosphorylase; Transplantation, Heterologous | 2003 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; E2F Transcription Factors; E2F1 Transcription Factor; Gemcitabine; Genes, Dominant; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Ribonucleoside Diphosphate Reductase; src-Family Kinases; Transcription Factors; Tyrosine | 2004 |
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2004 |
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Neoplasm Metastasis; Survival Rate | 2004 |
Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythrocyte Indices; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies | 2004 |
Retroviral IFN-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA, Complementary; Female; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Interferon-alpha; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Retroviridae; Transgenes | 2004 |
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Sarcoma | 2004 |
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Radiation Dosage; Retrospective Studies; Survival Analysis; Time Factors | 2004 |
Development of a green fluorescent protein metastatic-cancer chick-embryo drug-screen model.
Topics: Animals; Carcinoma, Lewis Lung; Chick Embryo; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Gemcitabine; Green Fluorescent Proteins; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Streptokinase | 2004 |
Impact of gemcitabine on the treatment of metastatic pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2005 |
New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: potential use for suppression of local recurrence of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Elastomers; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Polyurethanes; Prognosis; Secondary Prevention; Time Factors | 2005 |
Symptom-free T4 lung cancer with bilateral pulmonary artery infiltration.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Heart Neoplasms; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Pulmonary Artery; Radiography | 2005 |
Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyclohexanes; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; O-(Chloroacetylcarbamoyl)fumagillol; Pancreatic Neoplasms; Sesquiterpenes; Transplantation, Heterologous | 2005 |
Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Death; Deoxycytidine; Disease Models, Animal; Gemcitabine; Glutamates; Guanine; Liver Neoplasms; Male; Neoplasm Metastasis; Pemetrexed; Rats; Rats, Inbred Strains | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Heart Diseases; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Patient Selection; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Green Fluorescent Proteins; Humans; Image Processing, Computer-Assisted; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; Time Factors | 2005 |
Capecitabine-induced pancolitis.
Topics: Adult; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms | 2007 |
What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival; Taxoids; Vinblastine; Vinorelbine | 2005 |
Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
Topics: Adolescent; Adult; Alkaline Phosphatase; Analgesics, Non-Narcotic; Antigens, CD34; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Image Processing, Computer-Assisted; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Osteosarcoma; Pain; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Remission Induction; Samarium; Sarcoma; Stem Cells; Time Factors | 2005 |
Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2005 |
Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Pancreatic Neoplasms; Withholding Treatment | 2005 |
Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cells, Cultured; Coloring Agents; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Immunohistochemistry; Liver; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Chemical; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Organophosphorus Compounds; Pancreatic Neoplasms; Tetrazolium Salts; Thiazoles; Tubulin; Umbilical Veins | 2005 |
Gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Malaysia; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate | 2005 |
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caveolin 1; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2005 |
Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes.
Topics: Anthracyclines; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Dendritic Cells; Deoxycytidine; Disease Progression; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorouracil; Genes, Reporter; Green Fluorescent Proteins; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy; Interferon-gamma; Leukocytes, Mononuclear; Microscopy, Fluorescence; Neoplasm Metastasis; Remission Induction; RNA, Messenger; Taxoids; Time Factors; Transcription, Genetic; Treatment Outcome | 2005 |
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Neoplasm Metastasis; Phthalazines; Pyridines; Vascular Endothelial Growth Factor A | 2005 |
Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylserines; Transplantation, Heterologous | 2006 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Tegafur; Thiophenes; Treatment Outcome; Uracil | 2005 |
[Experience of gemcitabine plus cisplatin chemotherapy in 52 patients with head and neck cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2005 |
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mitomycin; Neoplasm Metastasis; Patient Selection; Prognosis; Reproducibility of Results; Treatment Outcome | 2006 |
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Thrombocytopenia | 2006 |
Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Thymidine Phosphorylase; Thyroglobulin; Thyroid Neoplasms | 2006 |
Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclohexanes; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Metastasis; O-(Chloroacetylcarbamoyl)fumagillol; Protein Structure, Tertiary; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Skin Neoplasms | 2006 |
Metastatic hidradenocarcinoma: efficacy of capecitabine.
Topics: Adenoma, Sweat Gland; Antimetabolites, Antineoplastic; Axilla; Capecitabine; Deoxycytidine; Diagnosis, Differential; Drug Administration Schedule; Elbow; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Sweat Gland Neoplasms | 2006 |
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Metastasis; Radiotherapy; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2006 |
Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; GTP-Binding Proteins; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Transglutaminases | 2006 |
Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Cell Proliferation; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proliferating Cell Nuclear Antigen; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Stomach Neoplasms; Survival Analysis | 2007 |
Treatment options for patients with pretreated metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Retreatment; Taxoids; Vinblastine; Vinorelbine | 2007 |
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured; Veratrum Alkaloids; Xenograft Model Antitumor Assays | 2007 |
Radiation recall pneumonitis induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Pneumonia; Radionuclide Imaging; Treatment Outcome | 2007 |
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Quinazolines; Regional Blood Flow; Signal Transduction; Skin; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD4-CD8 Ratio; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Endpoint Determination; Female; Fluorouracil; Humans; Immunotherapy; Killer Cells, Natural; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Analysis; Taxoids; Vascular Endothelial Growth Factor A | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Elementary, my dear Watson.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermatoglyphics; Dose-Response Relationship, Drug; Emigration and Immigration; Female; Fluorouracil; Foot; Hand; Humans; Neoplasm Metastasis | 2007 |
Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Platelet Aggregation Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome | 2007 |
Medullary thyroid cancer treated by capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Doxorubicin; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Thyroid Neoplasms; Treatment Outcome | 2007 |
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; RNA, Messenger; Treatment Outcome | 2007 |
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2007 |
Endoscopic ultrasound-guided fine-needle injection of immature dendritic cells into advanced pancreatic cancer refractory to gemcitabine: a pilot study.
Topics: Adult; Antimetabolites, Antineoplastic; Dendritic Cells; Deoxycytidine; Drug Resistance, Neoplasm; Endoscopy; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pilot Projects | 2007 |
[Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2007 |
Gemcitabine and cisplatin for advanced urothelial carcinomas: the Ehime University Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hospitals, University; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Urologic Neoplasms | 2007 |
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography | 2007 |
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Routes; Economics, Medical; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2007 |
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Failure | 2008 |
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromogranin A; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2008 |
[A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Treatment Outcome | 2007 |
Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; RNA, Small Interfering; Transfection | 2007 |
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Stomach Neoplasms | 2008 |
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Creatinine; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, Intravenous; Leukocyte Count; Male; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Platelet Count; Radioisotopes; Receptors, Somatostatin | 2008 |
Cancer-associated stromal fibroblasts promote pancreatic tumor progression.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Enzyme Activation; Fibroblasts; Gemcitabine; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Stromal Cells | 2008 |
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Trastuzumab; Treatment Failure | 2008 |
Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Hospitals, University; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
[A case of HER2-positive metastatic breast cancer responding to trastuzumab plus gemcitabine combination therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoembryonic Antigen; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiography; Receptor, ErbB-2; Tomography Scanners, X-Ray Computed; Trastuzumab | 2008 |
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Europe; Fluorouracil; Gastrointestinal Diseases; Humans; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Residence Characteristics; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States; Vitamin B Complex; Withholding Treatment | 2008 |
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Economics, Pharmaceutical; Fluorouracil; Hospital Costs; Humans; Models, Economic; Neoplasm Metastasis; Patient Selection; Research Design; Treatment Outcome | 2008 |
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Economics, Pharmaceutical; Fluorouracil; Hospital Costs; Humans; Infusions, Parenteral; Leucovorin; Models, Economic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Research Design; Treatment Outcome; Vitamin B Complex | 2008 |
Use of capecitabine in refractory metastatic medullary thyroid carcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Medullary; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Thyroid Neoplasms | 2008 |
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Colonic Neoplasms; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interleukin-2; Leucovorin; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Pilot Projects; Randomized Controlled Trials as Topic | 2007 |
Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase.
Topics: Animals; Breast Neoplasms; Cell Death; Cell Division; Deoxycytidine; Estrogens; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Ribonucleoside Diphosphate Reductase; Transplantation, Heterologous; Tumor Cells, Cultured | 1994 |
Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Deoxycytidine; Humans; Injections, Intraperitoneal; Injections, Intravenous; Leukocyte Count; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Survival Analysis; Transplantation, Heterologous | 1997 |
Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Pyrimidines; Subrenal Capsule Assay | 1998 |
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1999 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cetuximab; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Gemcitabine and cisplatin for advanced, metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Urinary Bladder Neoplasms; Vinblastine | 2001 |
[The expression of platelet-derived endothelial cell growth factor in liver cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Endothelial Growth Factors; Fluorouracil; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Platelet-Derived Growth Factor | 2000 |
Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyrimidines; Pyrroles; Ribonucleotide Reductases; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2001 |
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Clinical experience of capecitabine in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2002 |
Capecitabine monotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis | 2001 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2002 |
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retreatment | 2002 |
Effect of 5-azacytidine on DNA methylation and the malignant properties of B16 melanoma cells.
Topics: Animals; Azacitidine; Deoxycytidine; DNA, Neoplasm; Female; Lung Neoplasms; Melanoma; Methylation; Mice; Mice, Inbred C57BL; Neoplasm Metastasis | 1985 |